Report Sections

See All Reports

Coronavirus Infections (840) Severe Acute Respiratory Syndrome (575) Infection (491) Pneumonia (381) Communicable Diseases (217) Respiratory Distress Syndrome, Adult (187) Acute Lung Injury (148) Respiratory Distress Syndrome, Newborn (148) (134) Syndrome (129) Virus Diseases (98) Depression (92) Pneumonia, Viral (81) Critical Illness (69) Anxiety Disorders (57) Neoplasms (47) Respiratory Tract Infections (46) Disease (41) Diabetes Mellitus (39) Cardiovascular Diseases (38) Stress Disorders, Post-Traumatic (38) Emergencies (36) Wounds and Injuries (36) Depressive Disorder (35) Inflammation (35) Lung Diseases (33) Stress Disorders, Traumatic (33) Stress, Psychological (33) Respiratory Tract Diseases (31) Hypoxia (30) Lung Injury (30) Acute Kidney Injury (29) Mental Disorders (29) Thrombosis (29) Influenza, Human (27) Hypertension (25) Respiration Disorders (23) Disease Progression (22) Fibrosis (22) Cognitive Dysfunction (21) Olfaction Disorders (21) Arthritis (20) Diabetes Mellitus, Type 2 (20) Sclerosis (20) Burnout, Psychological (19) Multiple Sclerosis (19) Pulmonary Disease, Chronic Obstructive (19) Respiratory Aspiration (19) Thromboembolism (19) Embolism (18) Lung Diseases, Obstructive (18) Pulmonary Fibrosis (18) HIV Infections (17) Kidney Diseases (17) Stroke (17) Blood Coagulation Disorders (16) Heart Failure (16) Hemostatic Disorders (16) Pulmonary Embolism (16) Arthritis, Rheumatoid (15) Asthma (15) Chronic Disease (15) Heart Diseases (15) Lung Diseases, Interstitial (15) Lung Neoplasms (15) Myocardial Infarction (15) Substance-Related Disorders (15) Autism Spectrum Disorder (14) Chronic Pain (14) Crohn Disease (14) Brain Injuries (13) Diabetes Mellitus, Type 1 (13) Infarction (13) Venous Thrombosis (12) Autistic Disorder (11) Carcinoma (11) Colitis (11) Colitis, Ulcerative (11) Dyspnea (11) Feeding and Eating Disorders (11) Obesity (11) Rheumatic Diseases (11) Ulcer (11) Alzheimer Disease (10) Burnout, Professional (10) Leukemia (10) Lymphoma (10) Myocarditis (10) Overweight (10) Parkinson Disease (10) Pregnancy Complications (10) Renal Insufficiency, Chronic (10) Respiratory Syncytial Virus Infections (10) Sepsis (10) Brain Injuries, Traumatic (9) Collagen Diseases (9) Coronary Artery Disease (9) Cystic Fibrosis (9) Dementia (9) Depression, Postpartum (9) Frailty (9) Inflammatory Bowel Diseases (9) Liver Diseases (9) Musculoskeletal Pain (9) Pneumonia, Ventilator-Associated (9) Pulmonary Valve Insufficiency (9) Renal Insufficiency (9) Venous Thromboembolism (9) Vitamin D Deficiency (9) Weight Loss (9) Alcohol Drinking (8) Alcoholism (8) Hematologic Neoplasms (8) Infertility (8) Ischemia (8) Parasomnias (8) Problem Behavior (8) Psychotic Disorders (8) RNA Virus Infections (8) Breast Neoplasms (7) Convalescence (7) Coronary Disease (7) Dyssomnias (7) Fatigue (7) Metabolic Syndrome (7) Migraine Disorders (7) Myocardial Ischemia (7) Neoplasm Metastasis (7) Psoriasis (7) Schizophrenia (7) Shock (7) Spinal Cord Injuries (7) Toxemia (7) Acute Coronary Syndrome (6) Brain Diseases (6) Bronchiectasis (6) Carcinoma, Non-Small-Cell Lung (6) Child Development Disorders, Pervasive (6) Colorectal Neoplasms (6) Deglutition Disorders (6) Delirium (6) Disease Susceptibility (6) Immune System Diseases (6) Immunologic Deficiency Syndromes (6) Kidney Failure, Chronic (6) Lupus Erythematosus, Systemic (6) Lymphopenia (6) Multiple Organ Failure (6) Neurologic Manifestations (6) Osteoarthritis (6) (6) Pediatric Obesity (6) Prostatic Neoplasms (6) Sleep Apnea Syndromes (6) Sleep Apnea, Obstructive (6) Appendicitis (5) Arthritis, Psoriatic (5) Autoimmune Diseases (5) Coronaviridae Infections (5) Cross Infection (5) Depressive Disorder, Major (5) Dermatitis (5) Disseminated Intravascular Coagulation (5) Fibromyalgia (5) Gastroparesis (5) Head and Neck Neoplasms (5) Hypersensitivity (5) Idiopathic Pulmonary Fibrosis (5) Leukemia, Lymphoid (5) Metabolic Diseases (5) Mobility Limitation (5) Nervous System Diseases (5) Occupational Stress (5) Osteoarthritis, Knee (5) Pancreatic Neoplasms (5) Premature Birth (5) Triple Negative Breast Neoplasms (5) Acquired Immunodeficiency Syndrome (4) Acute Disease (4) Adenoviridae Infections (4) Amyotrophic Lateral Sclerosis (4) Anemia, Sickle Cell (4) Arrhythmias, Cardiac (4) Asymptomatic Diseases (4) Atrial Fibrillation (4) Attention Deficit Disorder with Hyperactivity (4) Behavior, Addictive (4) Body Weight (4) Carcinoma, Renal Cell (4) Cognition Disorders (4) Coinfection (4) Colonic Neoplasms (4) Death (4) Dermatitis, Atopic (4) Digestive System Diseases (4) Eczema (4) Embolism and Thrombosis (4) Endometriosis (4) Gastrointestinal Diseases (4) Headache (4) Heart Arrest (4) Hematologic Diseases (4) Hemophilia A (4) Hemorrhage (4) Hypertension, Pulmonary (4) Intestinal Diseases (4) Liver Cirrhosis (4) Macular Degeneration (4) Malnutrition (4) Motor Neuron Disease (4) (4) Mycobacterium Infections (4) Panic Disorder (4) Peripheral Arterial Disease (4) Postoperative Complications (4) Precursor Cell Lymphoblastic Leukemia-Lymphoma (4) Prediabetic State (4) Signs and Symptoms, Respiratory (4) Sjogren's Syndrome (4) Sleep Initiation and Maintenance Disorders (4) Spondylarthritis (4) Systemic Inflammatory Response Syndrome (4) Thrombophilia (4) Tobacco Use Disorder (4) Vascular Diseases (4) Ventricular Dysfunction (4) Ventricular Dysfunction, Left (4) Apnea (3) Bacteremia (3) Bacterial Infections (3) Bulimia (3) Cardiomyopathies (3) Celiac Disease (3) Cerebral Palsy (3) Chilblains (3) Common Cold (3) Congenital Abnormalities (3) Developmental Disabilities (3) Dysgeusia (3) Endocrine System Diseases (3) Eye Diseases (3) Fatigue Syndrome, Chronic (3) Fatty Liver (3) Fever (3) Fistula (3) Fractures, Bone (3) Ganglion Cysts (3) Giant Cell Arteritis (3) Glucose Intolerance (3) Glucose Metabolism Disorders (3) Heart Defects, Congenital (3) Hepatitis C (3) Huntington Disease (3) Hyperglycemia (3) Hypothermia (3) Kidney Calculi (3) Leukemia, Lymphocytic, Chronic, B-Cell (3) Leukemia, Myeloid, Acute (3) Macular Edema (3) Measles (3) Melanoma (3) Meningitis (3) Mouth Diseases (3) Mucocutaneous Lymph Node Syndrome (3) Multiple Myeloma (3) Multiple Sclerosis, Relapsing-Remitting (3) Myelodysplastic Syndromes (3) Myeloproliferative Disorders (3) Neoplasms, Plasma Cell (3) Neuroendocrine Tumors (3) Non-alcoholic Fatty Liver Disease (3) Obesity, Morbid (3) Obstetric Labor, Premature (3) Ovarian Neoplasms (3) Paramyxoviridae Infections (3) Peripheral Nervous System Diseases (3) Peripheral Vascular Diseases (3) Polymyalgia Rheumatica (3) Pregnancy Complications, Infectious (3) Psychological Trauma (3) Pulmonary Edema (3) Rare Diseases (3) Rheumatic Fever (3) ST Elevation Myocardial Infarction (3) Seizures (3) Shock, Septic (3) Sleep Wake Disorders (3) Small Cell Lung Carcinoma (3) Suicidal Ideation (3) Tachycardia (3) Taste Disorders (3) Tuberculosis (3) Ageusia (2) Agoraphobia (2) Alcoholic Intoxication (2) Alopecia (2) Alpha 1-Antitrypsin Deficiency (2) Angina Pectoris (2) Anxiety, Separation (2) Aortic Valve Stenosis (2) Arteritis (2) Asymptomatic Infections (2) Atherosclerosis (2) Atrophy (2) Back Pain (2) Behcet Syndrome (2) Binge-Eating Disorder (2) Bipolar Disorder (2) Bronchitis (2) Bronchitis, Chronic (2) Bronchopulmonary Dysplasia (2) Caliciviridae Infections (2) Carcinoma, Small Cell (2) Carcinoma, Squamous Cell (2) Cataract (2) Cholangitis (2) Clinical Deterioration (2) Clostridium Infections (2) Communicable Diseases, Emerging (2) Communication Disorders (2) Compassion Fatigue (2) Compulsive Personality Disorder (2) Conjunctivitis (2) Depressive Disorder, Treatment-Resistant (2) Diabetic Nephropathies (2) Diabetic Neuropathies (2) Diarrhea (2) Drug-Related Side Effects and Adverse Reactions (2) Emphysema (2) Endocarditis (2) Epilepsy (2) Facies (2) Fractures, Stress (2) Gastroenteritis (2) Gastroesophageal Reflux (2) Genetic Predisposition to Disease (2) Glioblastoma (2) Gout (2) Healthcare-Associated Pneumonia (2) Heart Failure, Systolic (2) Hepatitis (2) Hepatitis A (2) Humeral Fractures (2) Hyperkinesis (2) Hyperphagia (2) Hyperplasia (2) Hypertension, Pregnancy-Induced (2) Hypotension (2) Hypoventilation (2) Infertility, Male (2) Intervertebral Disc Degeneration (2) Ischemic Attack, Transient (2) Jaundice (2) Joint Diseases (2) Leukemia, Myeloid (2) Low Back Pain (2) Lymphedema (2) Lymphoma, B-Cell (2) Lymphoma, Mantle-Cell (2) Lymphoproliferative Disorders (2) Meningitis, Meningococcal (2) Mood Disorders (2) Mucositis (2) Muscle Spasticity (2) Muscular Dystrophies (2) Mutism (2) Mycoses (2) Myofascial Pain Syndromes (2) Myositis (2) Necrosis (2) Nephrolithiasis (2) Nerve Degeneration (2) Neurocognitive Disorders (2) Neurodevelopmental Disorders (2) Nidovirales Infections (2) Noncommunicable Diseases (2) Nutrition Disorders (2) Obsessive-Compulsive Disorder (2) Oral Manifestations (2) Oropharyngeal Neoplasms (2) Pain (2) Pain, Postoperative (2) Pancreatitis (2) Paresis (2) Periodontal Diseases (2) Phobia, Social (2) Phobic Disorders (2) Pneumonia, Bacterial (2) Pneumonia, Pneumocystis (2) Pre-Eclampsia (2) Preleukemia (2) Pulmonary Eosinophilia (2) Purpura, Thrombocytopenic, Idiopathic (2) Recurrence (2) Respiratory Sounds (2) Rupture (2) Sarcoidosis (2) Sarcopenia (2) (2) Scleroderma, Systemic (2) Spinal Diseases (2) Sprains and Strains (2) Squamous Cell Carcinoma of Head and Neck (2) Stillbirth (2) Stomatitis (2) Suicide (2) Temporomandibular Joint Disorders (2) Temporomandibular Joint Dysfunction Syndrome (2) Thoracic Diseases (2) Thrombocytopenia (2) Thyroid Diseases (2) Trauma and Stressor Related Disorders (2) Urinary Bladder, Overactive (2) Urinary Tract Infections (2) Uterine Cervical Neoplasms (2) Uveitis (2) Vision Disorders (2) Vision, Low (2) Wet Macular Degeneration (2) Yellow Fever (2) Abortion, Spontaneous (1) Abruptio Placentae (1) Acalculous Cholecystitis (1) (1) Adenocarcinoma (1) Adjustment Disorders (1) Adrenal Insufficiency (1) Aggression (1) Alcohol Drinking in College (1) Alcohol-Related Disorders (1) Altitude Sickness (1) Alveolitis, Extrinsic Allergic (1) Amblyopia (1) Anemia (1) Anemia, Aplastic (1) Anemia, Iron-Deficiency (1) Aneurysm (1) Aneurysm, Ruptured (1) Angina, Stable (1) Angioedema (1) Angioedemas, Hereditary (1) Ankle Fractures (1) Anorexia (1) Anorexia Nervosa (1) Arachnoiditis (1) Arthritis, Juvenile (1) Aspergillosis (1) Aspergillosis, Allergic Bronchopulmonary (1) Asphyxia Neonatorum (1) Asthenopia (1) Atrioventricular Block (1) Autonomic Nervous System Diseases (1) Barotrauma (1) Biliary Tract Neoplasms (1) Birth Weight (1) Blister (1) Body Weight Changes (1) Bone Diseases, Metabolic (1) Bone Marrow Diseases (1) Bradycardia (1) Brain Concussion (1) Brain Neoplasms (1) Breast Cancer Lymphedema (1) Bronchial Diseases (1) Bronchiolitis (1) Brucellosis (1) Bruxism (1) Bulimia Nervosa (1) (1) Calculi (1) Carcinoma in Situ (1) Carcinoma, Ductal (1) Carcinoma, Ductal, Breast (1) Carcinoma, Hepatocellular (1) Carcinoma, Intraductal, Noninfiltrating (1) Carcinoma, Ovarian Epithelial (1) Cardiotoxicity (1) Cardiovascular Abnormalities (1) Cellulitis (1) Cerebral Hemorrhage (1) Cerebrovascular Disorders (1) Chest Pain (1) Chlamydia Infections (1) Cholangiocarcinoma (1) Cholangitis, Sclerosing (1) Cholecystitis (1) Cholecystitis, Acute (1) Chorea (1) Chronic Traumatic Encephalopathy (1) Ciliary Motility Disorders (1) Colitis, Ulcerativ (1) Colonic Diseases (1) (1) Compulsive Behavior (1) Consciousness Disorders (1) Constipation (1) Constriction, Pathologic (1) Conversion Disorder (1) (1) Coronary Restenosis (1) Coronary Stenosis (1) (1) Coronavirus Infect (1) Cough (1) Coxsackievirus Infections (1) Crohn Dise (1) Cryopyrin-Associated Periodic Syndromes (1) Deafness (1) Death, Sudden, Cardiac (1) Dehydration (1) Dental Calculus (1) Dental Plaque (1) DiGeorge Syndrome (1) Diabetic Foot (1) Digestive System Neoplasms (1) Diphtheria (1) Down Syndrome (1) Drug Overdose (1) Dry Eye Syndromes (1) Dysentery, Bacillary (1) Dyskinesias (1) Dyspareunia (1) Dysphonia (1) Eclampsia (1) Emergence Delirium (1) Encephalitis (1) Endophthalmitis (1) Endotoxemia (1) Enterocolitis (1) Enterocolitis, Pseudomembranous (1) Enuresis (1) Eosinophilic Esophagitis (1) Epstein-Barr Virus Infections (1) Escherichia coli Infections (1) Esophageal Fistula (1) Esophageal and Gastric Varices (1) Esophagitis (1) Esophagitis, Peptic (1) Eye Infections (1) Fabry Disease (1) Facial Pain (1) Familial Mediterranean Fever (1) Femoral Fractures (1) Femoral Neck Fractures (1) Fetal Growth Retardation (1) Fetal Membranes, Premature Rupture (1) Fever of Unknown Origin (1) Food Hypersensitivity (1) Foot Ulcer (1) Fractures, Closed (1) Gait Disorders, Neurologic (1) Gambling (1) Gastrointestinal Stromal Tumors (1) Gaucher Disease (1) Genetic Diseases, Inborn (1) Geographic Atrophy (1) Gestational Weight Gain (1) Gingivitis, Necrotizing Ulcerative (1) Glomerulonephritis, IGA (1) Glomerulonephritis, Membranous (1) Guillain-Barre Syndrome (1) Halitosis (1) Headache Disorders, Secondary (1) Hearing Loss (1) Hearing Loss, Conductive (1) Heart Block (1) Heart Failure, Diastolic (1) Heart Murmurs (1) Helminthiasis (1) Hematoma (1) Hematoma, Subdural (1) Hematoma, Subdural, Chronic (1) Hemoglobinopathies (1) Hepatitis B (1) Hepatitis, Alcoholic (1) Hereditary Autoinflammatory Diseases (1) Herpes Labialis (1) Herpes Zoster (1) Hoarseness (1) Hodgkin Disease (1) Hot Flashes (1) Hyaline Membrane Disease (1) Hyperaldosteronism (1) Hypercapnia (1) Hyperkalemia (1) Hyperphosphatemia (1) Hypersensitivity, Immediate (1) Hypertrophy (1) Hypokalemia (1) Hyponatremia (1) Hypoparathyroidism (1) Iatrogenic Disease (1) (1) Infant, Newborn, Diseases (1) (1) Infec (1) Infecti (1) Infectious Mononucleosis (1) Infertility, Female (1) Intellectual Disability (1) Intermittent Claudication (1) Intestinal Atresia (1) Intracranial Aneurysm (1) Intracranial Hypertension (1) Intracranial Thrombosis (1) Jaundice, Obstructive (1) Keratoconjunctivitis (1) Keratoconjunctivitis Sicca (1) Keratosis (1) Keratosis, Actinic (1) Language Disorders (1) Leishmaniasis (1) Leukemia, Myelomonocytic, Acute (1) Leukemia, Myelomonocytic, Chronic (1) Leukemia, Prolymphocytic (1) Leukemia, Prolymphocytic, T-Cell (1) Lichen Sclerosus et Atrophicus (1) Liver Cirrhosis, Biliary (1) Liver Failure (1) Lung Ne (1) Lyme Disease (1) Lymphocytosis (1) Lymphoma, Large B-Cell, Diffuse (1) Lymphoma, Non-Hodgkin (1) Macrophage Activation Syndrome (1) Malaria (1) Maternal Death (1) Maxillofacial Injuries (1) May-Thurner Syndrome (1) Memory Disorders (1) Meningococcal Infections (1) Meningomyelocele (1) Menorrhagia (1) Menstruation Disturbances (1) Metabolism, Inborn Errors (1) Microvascular Rarefaction (1) Mitochondrial Diseases (1) Molluscum Contagiosum (1) Monoclonal Gammopathy of Undetermined Significance (1) Mouth, Edentulous (1) Movement Disorders (1) Multiple Chronic Conditions (1) Muscular Atrophy (1) Muscular Dystrophy, Duchenne (1) Myalgia (1) Myelodysplastic-Myeloproliferative Diseases (1) Myocardial Reperfusion Injury (1) Nasal Polyps (1) Needlestick Injuries (1) Neonatal Sepsis (1) Neoplasms, Germ Cell and Embryonal (1) Neoplastic Cells, Circulating (1) Nephritis (1) Nervous System Malformations (1) Neurobehavioral Manifestations (1) Neuromuscular Diseases (1) Neuromyelitis Optica (1) Obsessive Behavior (1) Olfactory Nerve Injuries (1) Oligospermia (1) Opioid-Related Disorders (1) Orbital Cellulitis (1) Osteoarthritis, Hip (1) Osteochondritis (1) Osteomyelitis (1) Otitis (1) Otitis Media (1) Otitis Media with Effusion (1) Overwei (1) Pain, Intractable (1) Pain, Procedural (1) Papillomavirus Infections (1) Paraproteinemias (1) Parkin (1) Peanut Hypersensitivity (1) Perinatal Death (1) Periodontal Pocket (1) Peritoneal Neoplasms (1) Pharyngeal Diseases (1) Pneumon (1) Polyps (1) Pregnancy in Diabetics (1) Presbyopia (1) Primary Dysautonomias (1) Primary Myelofibrosis (1) Prostatic Hyperplasia (1) Protein Deficiency (1) Protein-Energy Malnutrition (1) Pseudomonas Infections (1) Psychophysiologic Disorders (1) Puerperal Infection (1) Pulmonary Alveolar Proteinosis (1) Pulmonary Aspergillosis (1) Pulmonary Atelectasis (1) Pulmonary Heart Disease (1) Rabies (1) Radiculopathy (1) Rectal Fistula (1) Rectal Neoplasms (1) Reperfusion Injury (1) Resp (1) Respiratory Distre (1) Respiratory Distress Sy (1) Respiratory Hypersensitivity (1) Restless Legs Syndrome (1) Retinal Vein Occlusion (1) Rhinitis (1) Rhinitis, Allergic (1) Rhinitis, Allergic, Seasonal (1) Sarcoma (1) Schizophrenia Spectrum and Other Psychotic Disorders (1) Scleroderma, Localized (1) (1) Self-Injurious Behavior (1) Sexually Transmitted Diseases (1) Sexually Transmitted Diseases, Bacterial (1) Shock, Cardiogenic (1) Short Bowel Syndrome (1) Shoulder Fractures (1) Signs and Symptoms, Digestive (1) Skin Abnormalities (1) Skin Diseases (1) Skin Manifestations (1) Skin Neoplasms (1) Skull Fractures (1) Sleep Apnea, Central (1) Soft Tissue Neoplasms (1) Somatoform Disorders (1) Speech Sound Disorder (1) Spina Bifida Cystica (1) Spinal Cord Diseases (1) Spinal Dysraphism (1) Spinal Stenosis (1) Spondylitis (1) Spondylitis, Ankylosing (1) Spondylolisthesis (1) Status Epilepticus (1) Stress Disorders, Traumatic, Acute (1) Subarachnoid Hemorrhage (1) Superinfection (1) Syncope (1) Syncope, Vasovagal (1) Synovial Cyst (1) Tachycardia, Sinus (1) Tachycardia, Supraventricular (1) Tachycardia, Ventricular (1) Tachypnea (1) Thalassemia (1) Thrombophlebitis (1) Thrombotic Microangiopathies (1) Tissue Adhesions (1) Tonsillitis (1) Torsades de Pointes (1) Tourette Syndrome (1) Trauma, Nervous System (1) Trichuriasis (1) Tuberculosis, Meningeal (1) Tuberculosis, Pulmonary (1) Urinary Bladder Neoplasms (1) Urinary Bladder, Underactive (1) Urinary Incontinence (1) Urinary Retention (1) Urogenital Neoplasms (1) Urologic Diseases (1) Urticaria (1) Uterine Neoplasms (1) Vaginal Neoplasms (1) Venous Insufficiency (1) Ventricular Dysfunction, Right (1) Virus (1) Vitamin D Deficie (1) Voice Disorders (1) Von Willebrand Diseases (1) Vulvar Lichen Sclerosus (1) Vulvar Neoplasms (1) Waldenstrom Macroglobulinemia (1) Weight Gain (1) Xerostomia (1) beta-Thalassemia (1)

D015431: Weight Loss

Developed by Shray Alag, The Harker School
Sections: Correlations, Clinical Trials, and HPO

Correlations computed by analyzing all clinical trials.

Navigate: Clinical Trials and HPO


Correlated Drug Terms (23)


Name (Synonyms) Correlation
drug1346 Discussion Board for Social Support+Personalized Feedback Wiki 0.33
drug4651 Video Chat + Basic Feedback Wiki 0.33
drug4720 WW Wiki 0.33
Name (Synonyms) Correlation
drug1345 Discussion Board for Social Support +Basic Feedback Wiki 0.33
drug5097 nonfood-specific go/no-go computerized training Wiki 0.33
drug3092 Partner-assisted intervention Wiki 0.33
drug2980 Optifast VLCD Program Wiki 0.33
drug2990 Oral load of oxalate and sucralose Wiki 0.33
drug3110 Patient-only intervention Wiki 0.33
drug2095 In Person Behaviour Modification Program Wiki 0.33
drug2540 Med-South Weight Loss Intervention Wiki 0.33
drug2469 MOVE!+gshCBT Wiki 0.33
drug3642 Remote Behaviour Modification Program Wiki 0.33
drug2468 MOVE! Wiki 0.33
drug4743 Weight Loss Wiki 0.33
drug4652 Video Chat +Personalized Feedback Wiki 0.33
drug4955 food-specific go/no-go computerized training Wiki 0.33
drug2686 Multi Modal Balance Training Wiki 0.33
drug2981 Optifast VLCD Transition Phase Wiki 0.33
drug4750 Whole Health Program Wiki 0.33
drug2399 Low Oxalate Diet Wiki 0.24
drug906 Cannabidiol Wiki 0.24
drug3049 PLACEBO Wiki 0.19

Correlated MeSH Terms (6)


Name (Synonyms) Correlation
D053040 Nephrolithiasis NIH 0.24
D056912 Binge-Eating Disorder NIH 0.24
D050177 Overweight NIH 0.20
Name (Synonyms) Correlation
D002032 Bulimia NIH 0.19
D007669 Kidney Calculi NIH 0.19
D001068 Feeding and Eating Disorders NIH 0.10

Correlated HPO Terms (3)


Name (Synonyms) Correlation
HP:0001824 Weight loss HPO 1.00
HP:0000787 Nephrolithiasis HPO 0.24
HP:0100739 Bulimia HPO 0.19

Clinical Trials

Navigate: Correlations   HPO

There are 9 clinical trials


1 Multimodel Exercise and Weight Loss in Older Obese Veterans With Dysmobility

Obesity is a major risk factor for mobility problems in older adults and many older adults use a walking aid to help with their mobility. The use of a walking aid changes normal walking patterns and makes walking harder, leading people to have more functional problems. The purpose of this study is to test the effects of 12 months of a multi-modal balance intervention (MMBI) with supervised weight loss compared to MMBI only on fitness, functional performance, balance, and economy of gait. Participants will be one of 120 participants in the VAMHCS. Participation in this study is voluntary. The research will be conducted at the VAMHCS. The entire study will take approximately 4 years to complete. Subjects' participation in the study will last 24 months.

NCT02806336
Conditions
  1. Obesity
  2. Dysmobility
Interventions
  1. Behavioral: Multi Modal Balance Training
  2. Behavioral: Weight Loss
MeSH:Weight Loss
HPO:Decreased body weight Weight loss

Primary Outcomes

Description: Distance walked during the 6 minute walking test

Measure: Change in 6 minute walk distance

Time: baseline, 3 months, 6 months, 12 months, 24 months

Secondary Outcomes

Description: VO2peak measured during graded exercise treadmill test to volitional fatigue

Measure: Change in VO2peak

Time: baseline, 6 months, 12 months, 24 months

Description: 6 minute walk with submaximal assessment of oxygen uptake.

Measure: Change in 6 minute walk with VO2 measurement

Time: baseline, 3 months, 6 months, 12 months, 24 months

Description: DXA scan

Measure: Change in Muscle mass/body composition as assessed by DXA scan

Time: baseline, 6 months, 12 months, 24 months

Description: LLDFI Questionnaires

Measure: Change in Quality of Life, LLDFI

Time: baseline, 3 months, 6 months, 12 months, 24 months

Description: Gait biomechanics as assessed by walking mechanics on the GAITmat

Measure: Change in gait biomechanics

Time: baseline, 3 months, 6 months, 12 months, 24 months

Description: Component scores of the standing balance battery, usual gait speed, and repeated chair stands (which make up the short physical performance battery test); as well as overall short physical performance battery score

Measure: Change in short physical performance battery

Time: baseline, 3 months, 6 months, 12 months, 24 months

Description: Dynamic test of balance involving change in stepping direction.

Measure: Change in four square step test

Time: baseline, 3 months, 6 months, 12 months, 24 months

Description: Time to get up from a chair and walk around a cone 8 feet away and sit back down, representing agility.

Measure: Change in 8 foot up and go

Time: baseline, 3 months, 6 months, 12 months, 24 months

Description: CT scan

Measure: Change in Muscle mass/body composition as assessed by CT scan

Time: baseline, 6 months, 12 months, 24 months

Description: Self-reported ability to complete activities of daily living and independent activities of daily living.

Measure: Change in ADL/IADL questionnaire

Time: baseline, 3 months, 6 months, 12 months, 24 months

Description: Self-reported physical activities questionnaire.

Measure: Change in CHAMPS questionnaire

Time: baseline, 3 months, 6 months, 12 months, 24 months

Description: Questionnaire assessing global cognitive function

Measure: Change in MoCA

Time: baseline, 3 months, 6 months, 12 months, 24 months
2 Weight Loss Treatment and CBT for Veterans With Binge Eating

Inclusion Criteria: aged 21 and older, BMI>=25, and presence of recurrent binge eating on the MOVE! Survey. Exclusion Criteria: more than 4 MOVE! sessions in the prior year; active psychosis or suicidal ideation; medical or psychiatric illness, or cognitive deficits that interfere with providing consent or completing assessments, and; pregnancy or lactation. Participants will be recruited from the VA's MOVE! Program at VA Connecticut Healthcare System (both Newington and West Haven campuses). Those participants who meet eligibility and are interested in the study will meet with a research associate who will obtain written consent. A baseline appointment will be made where the participant will complete written assessments, anthropometric measures (weight, height, blood pressure etc.), along with a blood draw. Participants will then be randomized, by luck of a draw, to either MOVE! or MOVE!+gshCBT treatment. For those randomized to the MOVE! condition, participants will continue in the MOVE! program by meeting with the multidisciplinary team in a group setting once a week for 60 minutes, for 16 weeks. The group sessions are lead by a dietician, health psychologist, and physical therapist. For those randomized to the MOVE!+gshCBT treatments, participants will continue in the MOVE! program as described above, but will also partake in up to 10 individualized sessions over a 3-month period. Participants will be given a treatment manual to read at home, ask to complete daily food logs and work with the study therapist to create goals and complete homework that is geared at examining and changing how participant think about binge eating and how that thinking affects behavior. Lastly, a walking program will also be incorporated into the treatment. For both treatment arms, 3 months from treatment starting, then again at 9 months and 15 months, participants will be asked to complete post and follow up assessments, much like the baseline.

NCT03234881
Conditions
  1. Binge Eating Disorder
Interventions
  1. Behavioral: MOVE!
  2. Behavioral: MOVE!+gshCBT
MeSH:Weight Loss Bulimia Feeding and Eating Disorders Binge-Eating Disorder
HPO:Bulimia Decreased body weight Weight loss

Primary Outcomes

Description: The EDE-Q is the self-report version of the more intensive EDE interview. Research has documented that the EDE-Q performs well as a measure of change in treatment trials61and has adequate convergence with the interview format62,63. The EDE-Q generates the same frequency data for eating behaviors (binge eating and overeating) in the past 28 days, and the same four subscales reflecting eating disorder pathology.

Measure: Change in Eating Disorder Examination-Self-report Questionnaire (EDE-Q)

Time: Pre treatment, 3 month post treatment, 9 month post treatment, 15 month post treatment

Description: The EDE is a clinician administered interview that is considered to be the gold standard for diagnosing eating disorders and assessing binge frequency.

Measure: Change in Binge Episodes from Eating Disorder Examination Interview

Time: Pre Treatment, 3 month post treatment, 9 month post treatment, 15 month post treatment

Secondary Outcomes

Description: The PHQ-9 is a 9-item version, is a self-report measure for the symptoms of depression.

Measure: Change in Patient Health Questionnaire-9 (PHQ-9)

Time: Pre treatment, 3 month post treatment, 9 month post treatment, 15 month post treatment

Description: The PCL-5 is a 20-item self-report measure that assesses the 20 DSM-5 symptoms of Post Traumatic Stress Disorder (PTSD)

Measure: Change in PTSD Checklist (PCL-5)

Time: Pre treatment, 3 month post treatment, 9 month post treatment, 15 month post treatment

Description: The EuroQol-5D is a 5-item self-report instrument for measurement of quality of life outcomes that has specifically been used in weight loss trials with Veterans.

Measure: Change in European Quality of Life (EuroQoL-5D)

Time: Pre treatment, 3 month post treatment, 9 month post treatment, 15 month post treatment

Other Outcomes

Description: MOVE! group session attendance will be determined by the number of MOVE! group sessions attended throughout the treatment and follow-up phases.

Measure: Total number sessions of MOVE! group session attendance

Time: 3 month post treatment, 9 month post treatment, 15 month post treatment

Description: BMI will be calculated based upon weight in kilograms over height squared in centimeters. Weight will be measured by trained personnel using procedures based on the NHANES Anthropometry Procedures Manual70. Weight will be obtained using a high capacity digital platform scale that is regularly calibrated. Data will be obtained without shoes or coats. Height will be measured in duplicate using a wall-mounted stadiometer at baseline only. Weight data will additionally be collected weekly during treatment.

Measure: Change in BMI

Time: Pre treatment, 3 month post treatment, 9 month post treatment, 15 month post treatment

Description: The WCSS is a self-report instrument that assesses the use of specific weight loss behaviors. The measure has been shown to be valid, reliable and predictive of weight loss

Measure: Change in Weight Control Strategies Scale (WCSS)

Time: Pre treatment, 3 month post treatment, 9 month post treatment, 15 month post treatment

Description: FFQ is a brief dietary screening tool that measures intake of foods related to weight gain and loss.

Measure: Change in 24 Hour Food Frequency Questionnaire (24 Hour-FFQ)

Time: Pre treatment, 3 month post treatment, 9 month post treatment, 15 month post treatment

Description: The Godin is a 4-item, reliable self-report measure of physical activity that assesses the frequencies of strenuous, moderate and mild exercise and has been validated against accelerometers.

Measure: Change in Godin Leisure Time Exercise Questionnaire (Godin)

Time: Pre treatment, 3 month post treatment, 9 month post treatment, 15 month post treatment

Description: The 6MWT measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface. The test is used to detect changes following interventions to improve physical activity, and has been used with a wide range of populations including healthy and patient samples of children, adults and seniors. Overall, good reliability and validity have been reported for this measure although there is some variability depending upon patient sample used76. Among Veterans the measure has demonstrated good discriminant validity, and has detected changes following weight loss intervention.

Measure: Change in Six-Minute Walk Test (6MWT)

Time: Pre treatment, 3 month post treatment, 9 month post treatment, 15 month post treatment

Description: Treatment satisfaction will be measured with both open-ended questions (e.g., "What aspects of the intervention do you find most helpful? What aspects of the intervention do you find least helpful? What suggestions do you have to improve the program?") and closed-ended questions (e.g., "On a scale of 0 to 10, how would you rate your overall satisfaction with the intervention you received?" Responses range from 0=Completely Dissatisfied to 10=Completely Satisfied).

Measure: Treatment satisfaction

Time: 3 months post treatment

Description: Blood samples will be collected, after overnight fasting (12 hours), and analyzed for HbA1c.

Measure: Change in HbA1c

Time: Pre treatment, 3 month post treatment, 9 month post treatment, 15 month post treatment

Description: Blood samples will be collected, after overnight fasting (12 hours), and analyzed for Lipid Profile Analysis (total cholesterol, high-density lipoprotein cholesterol (HDL), low-density lipoprotein cholesterol (LDL), and triglycerides). Total cholesterol, HDL, LDL and triglycerides are measured by cholesterol levels in milligrams (mg) of cholesterol per deciliter (dL).

Measure: Change in Lipid Profile Analysis (Cholesterol)

Time: Pre treatment, 3 month post treatment, 9 month post treatment, 15 month post treatment

Description: Systolic and diastolic will be measured with a digital wrist blood pressure monitor and the average of three measurements, at each assessment point, will be used.

Measure: Change in Blood Pressure (BP)

Time: Pre treatment, 3 month post treatment, 9 month post treatment, 15 month post treatment

Description: Waist Circumference will be measured in inches, and will be assessed with a measuring tape placed horizontally just above the iliac crest, after completion of a respiratory cycle.

Measure: Change in Waist Circumference

Time: Pre treatment, 3 month post treatment, 9 month post treatment, 15 month post treatment

Description: Status determined by a diabetes diagnosis in the electronic health record.

Measure: Diabetes Status (covariate)

Time: Pre treatment

Description: Heart rate will be taken with a digital wrist blood pressure monitor and the average of three measurements, at each assessment point. Heart rate is measured in beats per minute.

Measure: Change in Heart Rate (HR)

Time: Pre treatment, 3 month post treatment, 9 month post treatment, 15 month post treatment

Description: Use determined by statin prescription in the electronic health record. Scores are dichotomous (Yes/No) with YES being worse.

Measure: Statin Use (covariate)

Time: Pre treatment

Description: A self-administered scale used to assess features of loss of control over eating.

Measure: Loss of Control Overeating Scale (LOCES)

Time: Pre Treatment, 3 month post treatment, 9 month post treatment, 15 month post treatment

Description: A self-administered scale used to assess the features of food addiction. Scores range from 0-28 with higher scores reflecting worse outcome.

Measure: Modified Yale Food Addiction Scale 2.0 (mYFAS 2.0)

Time: Pre Treatment, 3 month post treatment, 9 month post treatment, 15 month post treatment
3 Using Partners to Enhance Long-Term Weight Loss

This study involves an evaluation of the role of domestic partner support in a comprehensive weight loss initiation and maintenance program.

NCT03801174
Conditions
  1. Obesity
Interventions
  1. Behavioral: Partner-assisted intervention
  2. Behavioral: Patient-only intervention
MeSH:Weight Loss
HPO:Decreased body weight Weight loss

Primary Outcomes

Description: Measured on a calibrated, digital scale to the nearest 0.1 kg, assessed every 6 months with 24 months as primary endpoint

Measure: Body weight (kg)

Time: 24 months

Secondary Outcomes

Description: average estimated daily intake from ASA24 Dietary Assessment Tool, assessed every 6 months with 24 months as primary endpoint

Measure: Caloric intake (kcal)

Time: 24 months

Description: average daily minutes of moderate activity over past 7 days from Fitbit, assessed every 6 months with 24 months as primary endpoint

Measure: Physical activity

Time: 24 months

Other Outcomes

Description: Score based on 12-item Unidimensional Relationship Closeness Scale (1-7, strongly disagree to strongly agree) and single-item Inclusion of Other in Self scale (7 Venn diagrams)

Measure: Transformation of motivation for diet

Time: 3 months

Description: 5 items assessed on 11-point scale ranging from 0 (not at all effective) to 10 (very effective)

Measure: Outcome efficacy for diet

Time: 3 months

Description: 5 items assessed on 11-point scale ranging from 0 (not at all confident) to 10 (very confident)

Measure: Couple efficacy for diet

Time: 3 months

Description: 9 items assessed on 5-point scale (never, rarely, sometimes, often, almost always)

Measure: Social support for diet

Time: 3 months

Description: 5 items assessed on 5-point frequency scale (never, sometimes, frequently, often, very often)

Measure: Use of communal coping strategies for diet

Time: 3 months

Description: Score based on 12-item Unidimensional Relationship Closeness Scale (1-7, strongly disagree to strongly agree) and single-item Inclusion of Other in Self scale (7 Venn diagrams)

Measure: Transformation of motivation for physical activity

Time: 3 months

Description: 5 items assessed on 11-point scale ranging from 0 (not at all effective) to 10 (very effective)

Measure: Outcome efficacy for physical activity

Time: 3 months

Description: 5 items assessed on 11-point scale ranging from 0 (not at all confident) to 10 (very confident)

Measure: Couple efficacy for physical activity

Time: 3 months

Description: 9 items assessed on 5-point scale (never, rarely, sometimes, often, almost always)

Measure: Social support for physical activity

Time: 3 months

Description: 5 items assessed on 5-point frequency scale (never, sometimes, frequently, often, very often)

Measure: Use of communal coping strategies for physical activity

Time: 3 months
4 Randomized Explanatory Trial of a Mediterranean Dietary Pattern Weight Loss Intervention for Primary Care Practices

This study will compare a new weight loss program that focuses on a healthy eating pattern, with WW™ (formally Weight Watchers), an effective and widely available weight loss program. Study researchers have developed an adapted version of the Mediterranean eating pattern to be more acceptable and realistic for southerners; this adapted version is known as "Med-South." Those who take part in the study will be randomly assigned to either the Med-South weight loss program or WW™. Both programs will last for 2 years with measurement visits at the start of the study and at 4-, 12- and 24-month follow-up. While the primary outcome measured by the trial will be weight loss at 24 months, researchers will collect other data which may show additional health benefits of the Med-South diet. The study team will measure blood markers of inflammation, which are known to improve with better diet quality. Researchers will also measure participants' skin carotenoid levels, which increase with greater fruit and vegetable consumption. The study will be conducted within 2 regional catchment areas (n=360 participants) representing a diverse spectrum of patients and settings. Patients with a BMI ≥ 30 kg/m^2 will be enrolled and randomized to intervention or augmented usual care. To assure adequate subgroup representation, ≥ 40% of the sample will have diabetes, ≥ 40% will be male, and ≥ 40% will be African American. The intervention will be delivered in 3 phases over 24 months by research staff: Phase I (4 months) focuses on adopting a Med-style dietary pattern; Phase II (8 months) on weight loss; and Phase III (12 months) on weight loss maintenance. Outcomes will be assessed at 4, 12, and 24 months. The primary outcome is weight loss at 24 months. Secondary outcomes include change in physiologic, behavioral, and psychosocial measures. Researchers will also assess implementation cost and the incremental cost-effectiveness of the intervention relative to the augmented usual care group.

NCT04302727
Conditions
  1. Weight Loss
  2. Diet, Healthy
  3. Card
  4. Cardiovascular Risk Factor
Interventions
  1. Behavioral: Med-South Weight Loss Intervention
  2. Behavioral: WW
MeSH:Weight Loss
HPO:Decreased body weight Weight loss

Primary Outcomes

Description: Weight will be collected by study staff who are masked to treatment using scales tested monthly for accuracy up to 350 pounds.

Measure: Mean Weight Change from Baseline to Month 24

Time: Baseline, Month 24

Secondary Outcomes

Description: Weight will be collected by study staff who are masked to treatment using scales tested monthly for accuracy up to 350 pounds.

Measure: Mean Weight Change from Baseline to Months 4 and 12

Time: Baseline, Months 4 and 12

Description: Weight will be collected by study staff who are masked to treatment using scales tested monthly for accuracy up to 350 pounds. Change in weight will be assessed across 3 pre-specified subgroups: 1) with vs. without diabetes; 2) females vs. males; and 3) whites vs. African Americans.

Measure: Mean Weight Change from Baseline through Follow-Up by Sub-Groups

Time: Baseline, Months 4, 12, and 24

Description: Weight will be collected by study staff who are masked to treatment using scales tested monthly for accuracy up to 350 pounds. Assess difference between study groups in percentage losing ≥ 5% body weight for all participants and across 3 pre-specified subgroups: 1) participants with vs. without diabetes; 2) females vs. males; and 3) Whites vs. African Americans.

Measure: Percentage Weight from Baseline through Follow-Up

Time: Baseline, Months 4, 12, and 24

Description: Blood pressure assessed by Omron-907xl, average of 3 readings.

Measure: Mean Change in Systolic Blood Pressure from Baseline through Follow-Up

Time: Baseline, Months 4, 12, and 24

Description: Blood pressure assessed by Omron-907xl, average of 3 readings.

Measure: Mean Change in Diastolic Blood Pressure from Baseline through Follow-Up

Time: Baseline, Months 4, 12, and 24

Description: Total cholesterol assessed by commercial lab (LabCorp).

Measure: Mean Change in Total Cholesterol from Baseline through Follow-Up

Time: Baseline, Month 4, 12, and 24

Description: HDL-Cholesterol assessed by commercial lab (LabCorp).

Measure: Mean Change in HDL-Cholesterol from Baseline through Follow-Up

Time: Baseline, Month 4, 12, and 24

Description: Triglycerides as assessed by commercial lab (LabCorp).

Measure: Mean Change in Triglycerides from Baseline through Follow-Up

Time: Baseline, Month 4, 12, and 24

Description: Calculated from above lipid assessments by commercial lab (LabCorp).

Measure: Mean Change LDL-cholesterol from Baseline through Follow-up

Time: Baseline, Month 4, 12, and 24

Description: A1c assessed by commercial lab (LabCorp).

Measure: Mean Change in A1c from Baseline through Follow-Up

Time: Baseline, Month 4, 12, and 24

Description: CRP assessed by commercial lab (LabCorp).

Measure: Mean Change in CRP from Baseline through Follow-Up

Time: Baseline, Month 4, 12, and 24

Description: Assessed by independent lab blinded to participant arm.

Measure: Mean Change in IL-6 from Baseline through Follow-Up

Time: Baseline, Month 4, 12, and 24

Description: Assessed by independent lab blinded to participant arm.

Measure: Mean Change in TNF-alpha from Baseline through Follow-Up

Time: Baseline, Month 4, 12, and 24

Description: Evaluated as the sum of 3 measures assessed by veggie-meter by Longevity Link Corporation.

Measure: Mean Change in Skin Carotenoids from Baseline through Follow-Up

Time: Baseline, Month 4, 12, and 24

Description: The Euro Quality of Life five Dimensions Questionnaire EQ-5D-5L scale measures patients' quality of healthy living. It has 5 items (Mobility, Self-care, Usual activities, Pain/discomfort, Depression/anxiety). Each item contains 5 levels: 1= no difficulty, 2= slight difficulty, 3= moderate difficulty, 4= serious difficulty, 5= extremely serious difficulty. The higher the score has the worse the health. Then, the score calculation of the European Five-Dimensional Health Scale is based on the calculation formula published by the EuroQol Group. Based on 5 combinations of different severity levels, a score of 0 to 1 is obtained. 0 is the least healthy and 1 is the most healthy.

Measure: Mean Change in Quality of Life Scale from Baseline through Follow-Up

Time: Baseline, Month 4, 12, and 24

Description: The AHEI-2010 is calculated from items on the Willett Food Frequency Questionnaire. It addresses intake of foods and nutrients consistently associated with lower risk for chronic diseases in the literature. The AHEI-2010 score is comprised of 11 sub-scales, each scored from 0 to 10, yielding a total score with a range of 0-110. A higher score indicates a more healthful dietary pattern.

Measure: Mean Change in Alternate Healthy Eating Index (AHEI)-2010 from Baseline through Follow-Up

Time: Baseline, Month 4, 12, and 24

Description: The GPAQ was developed by the WHO for physical activity surveillance. It collects information on physical activity participation in three settings (or domains) as well as sedentary behavior. The domains are: activity at work, travel to and from places, and recreational activities. The summary measure will be the sum of all activity per day with a higher score indication more physical activity.

Measure: Mean Change in Global Physical Activity Questionnaire (GPAQ) from Baseline through Follow-Up

Time: Baseline, Month 4, 12, and 24

Description: The Weight Efficacy Lifestyle Questionnaire Short-Form (WEL-SF1) is a short version of the original Weight-Efficacy Lifestyle Questionnaire and includes 8 questions and 1 situational component representing "confidence in ability to resist eating." Three of the questions are related to emotional eating situations, two to availability, one to social pressure, one to positive activities, and one to physical discomfort. Scoring: The instrument range scores on a Likert-scale from 0 (not at all confident) to 10 (very confident), with sum scores between 0 and 80. High scores are associated with high eating self-efficacy.

Measure: Mean Change in Weight Loss Self-Efficacy from Baseline through Follow-Up

Time: Baseline, Month 4, 12, and 24

Description: Treatment Self-regulation Questionnaire (TSRQ) measures the quality of motivation for a particular health goal. Motivation is psychological energy directed at a particular goal such as weight loss. This measure assesses three types of motivation: autonomous self-regulation, controlled self-regulation, and a-motivation or lack of motivation. This 15-item scale will focus on the reasons why people would either start eating a healthier diet or continue to do so. Scoring: Participants rate each statement on a 7-point Likert scale ranging from 1 (not at all true) to 7 (very true). It assesses the degree to which a person's motivation for eating a healthy diet is autonomous or self-determined. The three sub-scale scores can be used separately or a Relative Autonomous Motivation score can be calculated. A higher score indicates greater motivation.

Measure: Mean Change in Dietary Self-Regulation from Baseline through Follow-Up

Time: Baseline, Month 4, 12, and 24

Description: The Three Factor Eating Questionnaire (18 item revised version) measures eating attitudes with scales representing three dimensions of eating behavior: cognitive restraint (control over food intake in order to influence body weight / body shape), uncontrolled eating (loss of control over eating), and emotional eating (eating in response to positive and negative emotions). Scoring: Each scale (dimension) is scored separately. Six of the eighteen items measure cognitive restraint, nine measure uncontrolled eating, and three measure emotional eating. Higher scores indicate greater cognitive restraint.

Measure: Mean Change in Eating Attitudes from Baseline through Follow-Up

Time: Baseline, Month 4, 12, and 24

Description: Perceived self-efficacy is regarded as a suitable predictor of behavioral intentions and reported health behaviors. This 5-item scale of perceived self-efficacy measuring action self-efficacy and coping self-efficacy related to healthful eating behaviors. Responses are on a 4-point scale of 'very uncertain' to 'very certain.' Scoring: Higher scores indicate higher perceived self-efficacy. Validation: Evidence for the validity of the scales has been published in several articles. Cronbach's alpha for the nutrition self-efficacy measure ranges from 0.79 to 0.85.

Measure: Mean Change in Diet Self-Efficacy from Baseline through Follow-Up

Time: Baseline, Month 4, 12, and 24

Description: EARLY Self-Weighing Questionnaire: This is a 2-item screener measures frequency of self-weighing and access to a bathroom scale. It was adapted from the Pound of Prevention Health Habits Questionnaire, Year 2. Validity of construct confirmed in Linde et al, 2005, as reports of higher weighing frequency was associated with greater 24-month weight loss or less weight gain. Scoring: Higher scores indicate higher frequency of self-weighing and access to a bathroom scale.

Measure: Mean Change in Self-Weighing Behaviors from Baseline through Follow-Up

Time: Baseline, Month 4, 12, and 24

Description: Computed as the incremental cost per kilogram of weight loss relative to control. The budgetary assessment will quantify the total and per participant costs of intervention delivery from the health system perspective using an Activity Based Costing (ABC) approach and cost tracking forms that the health economist (Finkelstein) has developed and refined in past behavioral trials. Using this approach, all relevant labor, materials and supplies, contracted services, and other relevant costs required to deliver the interventions will be captured by key activities

Measure: Economic Outcome--Incremental Cost-Effectiveness

Time: Month 24

Description: The numerator for this analysis will be the incremental program delivery costs of the intervention relative to control, minus any cost offsets based on differences in health services and medication use across arms. The denominator will be the incremental QALYs based on average differences in Euro Quality of Life five Dimensions Questionnaire (EQ-5D-5L) scores across arms collected at each assessment point. These scores can be used to quantify net QALY differences during the intervention period. EQ-5D-5L scale measures patients' quality of healthy living. It has 5 items (Mobility, Self-care, Usual activities, Pain/discomfort, Depression/anxiety). The score calculation of the European Five-Dimensional Health Scale is based on the calculation formula published by the EuroQol Group. Based on 5 combinations of different severity levels, a score of 0 to 1 is obtained. 0 is the least healthy and 1 is the most healthy.

Measure: Economic Outcome--Incremental Cost per Quality Adjusted Life Year (QALY) gained

Time: Month 24
5 Exploring the Optimal Treatment Components for a Contactless Online Group-based Behavioral Weight Loss Program for the COVID 19 Pandemic

The current pilot study will explore the optimal cost-effective treatment configuration for online group-based weight control by focusing on two aspects of our existing treatment program which have significant associated cost and determine which contribute meaningfully to weight loss outcomes. Specifically, we will explore whether adding synchronous group social support (weekly group video chat sessions facilitated by a trained weight loss counselor) to on demand (asynchronous) social support provided through the program discussion board significantly increases weight losses achieved. We will also examine whether detailed feedback on dietary and physical activity self-monitoring records from a counselor enhances weight loss outcomes in comparison with basic feedback. Finally, we will examine the cost efficiency of the treatment constellations. Further, this pilot study will also explore the feasibility of recruiting participants nationally (rather than just locally) and the capture of data electronically (including body weight measurements) without any in-person contact.

NCT04514900
Conditions
  1. Obesity
Interventions
  1. Behavioral: Video Chat +Personalized Feedback
  2. Behavioral: Video Chat + Basic Feedback
  3. Behavioral: Discussion Board for Social Support +Basic Feedback
  4. Behavioral: Discussion Board for Social Support+Personalized Feedback
MeSH:Weight Loss
HPO:Decreased body weight Weight loss

Primary Outcomes

Description: Change in body weight from baseline calculated as kg lost

Measure: Weight loss

Time: Baseline, 2 and 4 months

Description: 1 - [follow-up body weight/ baseline body weight] = % body weight change

Measure: Change in body weight from baseline calculated as % of body weight lost

Time: 2 and 4 months

Secondary Outcomes

Description: Self-monitoring rates for daily weighing and will be calculated as the total number of days of weight submitted over the 4 month period divided by the total number of days of potential self-weighing.

Measure: Treatment Engagement: daily weighing

Time: Weeks 1 to 16

Description: Self-monitoring rates for daily dietary self monitoring will be calculated as the total number of weeks of digital food diaries submitted over the 4 month period divided by the total number of weeks of potential digital diary submissions.

Measure: Treatment Engagement: weekly food journal submissions

Time: Weeks 1 to 16

Description: Percent of weekly module completion will be calculated as the total number of weeks of completed modules submitted over the 4 month period divided by 16 (the total number of modules available).

Measure: Treatment Engagement: completion of the 16 weekly interactive online modules

Time: Weeks 1 to 16

Description: Percent of weekly video chat attendance will be calculated as the total number of weeks each participant attended video chat over the 4 month period divided by 16 (the total number of video chats available).- Collected only for those randomized to a condition with video chat

Measure: Treatment Engagement: Attendance at Video Chat condition

Time: Weeks 1 to 16

Other Outcomes

Description: All participants will be administered the Supportive Accountability Questionnaire to determine whether there is a difference in accountability experienced by participants depending on which intervention they receive.

Measure: Supportive Accountability

Time: 2 months and 4 months

Description: All participants will be administered the Perceived Social Support Scale to determine whether perceptions of social support differ depending on which intervention participants receive.

Measure: Social Support

Time: baseline, 2 months and 4 months

Description: Actual counselor time spent in delivering group video chats and giving feedback will be tracked in order to quantify the relative costs of delivering behavioral weight control programs.

Measure: Cost-Effectiveness Analyses

Time: Weeks 1 to 16

Description: All participants will be queried as to their expectations and preferences in treatment prior to intervention.using a measure designed for the current study

Measure: Treatment Expectations

Time: Baseline

Description: Each month participants will be asked to complete a survey inquiring about the helpfulness of the treatment modules, skills building assignments, and satisfaction with their treatment experiences in the previous month. Response options will be a 5-point Likert scale with 1=not at all helpful/useful and 5=extremely helpful/useful on a measure that is developed for this study and tailored to the treatment elements provided.

Measure: Treatment Satisfaction

Time: through study completion, up to 24 weeks

Description: Participants self report on their self management behaviors

Measure: Self Regulation Questionnaire

Time: baseline
6 The Effect of Go/No-Go Training Dosage on Weight Loss, Food Evaluation, and Disinhibition in Overweight and Obese Individuals: A Randomized Controlled Trial

The purpose of this study is to assess the effect of a food-specific Go/No-Go (GNG) computerized training task on weight loss, food evaluation, and disinhibition in a population of overweight and obese individuals.

NCT04624087
Conditions
  1. Overweight and Obesity
Interventions
  1. Behavioral: food-specific go/no-go computerized training
  2. Behavioral: nonfood-specific go/no-go computerized training
MeSH:Overweight Weight Loss
HPO:Decreased body weight Weight loss

Primary Outcomes

Description: Body weight will be measured by participant using personal or university scale. Participants will take a picture of their weight send it to the research team (Due to COVID-19 precautions, in person weighing is not possible).

Measure: Change in body weight from baseline to post 4-week intervention, to 6-month follow-up

Time: baseline, post 4-week intervention, 6-month follow-up

Description: This will be measured using the Disinhibition subscale of the Three Factor Eating Questionnaire; minimum value = 0; maximum value = 16; higher scores for this measure means worse outcomes

Measure: Change in disinhibition scores from baseline to post 4-week intervention, to 6-month follow-up.

Time: baseline, post 4-week intervention, 6-month follow-up

Description: This will be measured using a food frequency questionnaire assessing food intake over the previous month.

Measure: Change in frequency of food consumption from baseline to post 4-week intervention, to 6-month follow-up.

Time: baseline, post 4-week intervention, 6-month follow-up

Secondary Outcomes

Description: This will be measured using the binge eating questions of the Eating Disorder Examination Questionnaire; minimum value = 0; maximum value = unlimited; higher scores for this measure means worse outcomes

Measure: Change in binge eating behaviors from baseline to post 4-week intervention, to 6-month follow-up.

Time: baseline, post 4-week intervention, 6-month follow-up

Description: This will be measured using a visual analog scale; minimum value = -100; maximum value = 100; higher scores for this measure on healthy foods means better outcomes, higher scores on this measure for unhealthy foods means worse outcomes

Measure: Change in liking of foods from baseline to post 4-week intervention, to 6-month

Time: baseline, post 4-week intervention, 6-month follow-up

Description: This will be measured using an impulsive food choice test.

Measure: Change in automatic responses to healthy and unhealthy foods from baseline to post 4-week intervention, to 6-month

Time: baseline, post 4-week intervention, 6-month follow-up
7 Effect of Weight Loss on Urinary Oxalate Excretion in Obese Calcium Oxalate Kidney Stone

This protocol seeks to determine if weight reduction with the Optifast VLCD program leads to reduced contribution of endogenous oxalate synthesis to the urinary oxalate pool in obese calcium oxalate stone formers.

NCT04633811
Conditions
  1. Kidney Stone
Interventions
  1. Dietary Supplement: Low Oxalate Diet
  2. Dietary Supplement: Oral load of oxalate and sucralose
  3. Dietary Supplement: Optifast VLCD Program
  4. Dietary Supplement: Optifast VLCD Transition Phase
MeSH:Kidney Calculi Nephrolithiasis Weight Loss
HPO:Decreased body weight Nephrolithiasis Weight loss

Primary Outcomes

Description: Subjects will ingest a controlled diet low in oxalate and collect 2 x 24-hour urines before and after the Optifast VLCD Program. The utilization of a low oxalate diet allows assessment of the change in contribution of endogenous oxalate synthesis to the urinary oxalate pool.

Measure: Measurement of 24 hour urinary oxalate excretion

Time: Day 4
8 A Mixed Retrospective-prospective, Observational Study Evaluating the Efficacy of Counselling in a Remote Setting Compared to an In-person Setting on Weight Loss, in Obese Patients With Body Mass Index > 35 Kg/m2 and Enrolled in the Behaviour Modification Program at the Bariatric Centre of Excellence at St Joseph's Healthcare Hamilton.

The COVID-19 pandemic has created fear, financial difficulties and interruptions in the lives of patients and healthcare providers. As a result, many patients suffering from chronic conditions such as obesity have had their treatment disrupted by the pandemic. The Bariatric Medical Weight Management Clinic at St. Joseph's Healthcare Hamilton transitioned its weight loss and maintenance counselling classes to a remote (online) platform in response to the pandemic. The remote weight loss and maintenance classes allows patients to continue receiving treatment for obesity from their homes. The remote weight loss and maintenance program is conducted on a safe platform that has been thoroughly reviewed and approved by St. Joseph's Privacy Committees. The aim of this study is to learn whether the remote weight loss and maintenance classes can lead to similar weight loss compared to the in-person weight loss and maintenance classes that were offered to patients before the COVID-19 pandemic. This study also aims to gather feedback about the program to improve its delivery and patients' experiences.

NCT04658550
Conditions
  1. Obesity
Interventions
  1. Other: Remote Behaviour Modification Program
  2. Other: In Person Behaviour Modification Program
MeSH:Weight Loss
HPO:Decreased body weight Weight loss

Primary Outcomes

Description: To evaluate the efficacy of counselling in a remote setting compared to an in-person setting in achieving weight loss among adult patients with obesity enrolled in the behaviour modification program

Measure: Mean Percentage Change in Body Weight

Time: Baseline to Week 26

Secondary Outcomes

Description: Patient satisfaction and barriers to participation associated with the remote weight loss and maintenance program as assessed by the Bariatric Centre of Excellence Virtual Medical Program Satisfaction Survey.

Measure: Patient satisfaction and barriers to participation

Time: Week 26

Description: Change in blood pressure

Measure: Change in blood pressure

Time: Baseline to Week 26

Description: Change in lipid profile including total cholesterol, triglycerides, low density lipoprotein and high density lipoprotein

Measure: Change in lipid profile

Time: Baseline to Week 26

Description: Change in fasting blood glucose

Measure: Change in fasting blood glucose

Time: Baseline to Week 26

Description: Change in heart rate

Measure: Change in heart rate

Time: Baseline to Week 26

Description: Change in HbA1C

Measure: Change in HbA1C

Time: Baseline to Week 26
9 Koa Family Study--A Community-Based Intervention to Improve Health and Well-Being

Wholehearted living touches every aspect of life, from eating nourishing foods, to enjoying enough physical activity, to cultivating relationships that support healthy choices, to joining with neighbors to stand up for positive changes, and more. Unfortunately, for many low-income Californians, the idea of wholehearted living is an aspiration and not a reality. Koa Family: Strong, Healthy, Whole is an approach designed to make wholehearted living available for all. The Approach Koa Family is a 4-month journey to establish "micro-communities" of women supporting one another- mind, body, and spirit. The foundation of this approach is a new, custom-designed, online Whole Health Program (WHP) that addresses healthy eating, physical activity, and weight management within the context of wholehearted living. Low-income women and a lifestyle coach will meet weekly in a virtual platform to learn, experience, grow, and thrive as they reach their diet, physical activity, and weight management goals. Participants in the WHP will receive additional encouragement and access to local resources through a private and secure Facebook group. The group will provide a place for women to continue their wholehearted health journeys beyond the weekly meetings. Koa Family participants also will be invited to take part in a neighborhood tree planting campaign to create real, long-lasting, healthy changes to the environment in which they live. The Study Koa Family, with WHP at its core, is the product of extensive formative research both nationally and within low-income California communities. Koa Family will be introduced in Sacramento County in February 2021. It will be evaluated for effectiveness among 120 low-income, Supplemental Nutrition Assistance Program (SNAP)-Ed eligible women using a randomized controlled trial study design, the gold standard for assessing effectiveness of an intervention. Outcomes include changes in Body Mass Index, diet, and physical activity measured at 4 and 6 months from baseline. An economic analysis will assess the cost-effectiveness of Koa Family, while qualitative methods will identify mediating factors related to the study outcomes. Funding Koa Family is a project of the Population Health Group at the University of California, Davis, Center for Healthcare Policy and Research. Funding is provided by the United States Department of Agriculture Supplemental Nutrition Assistance Program-Education and the California Department of Forestry and Fire Protection (CalFIRE).

NCT04662593
Conditions
  1. Obesity
  2. Overweight
  3. Diet, Healthy
  4. Social Interaction
  5. Weight Loss
Interventions
  1. Behavioral: Whole Health Program
MeSH:Overweight Weight Loss
HPO:Decreased body weight Weight loss

Primary Outcomes

Description: Weight (kg) measured with an electronic scale

Measure: Change from Baseline Weight at 4 Months

Time: Difference in weight between baseline and 4 months

Description: Weight (kg) measured with an electronic scale

Measure: Change from Baseline Weight at 6 Months

Time: Difference in weight between baseline and 6 months

Description: weight (kg)/height (m) x height (m)

Measure: Change from Baseline Body Mass Index (BMI) at 4 Months

Time: Difference in BMI between baseline and 4 months

Description: weight (kg)/height (m) x height (m)

Measure: Change from Baseline Body Mass Index (BMI) at 6 Months

Time: Difference in BMI between baseline and 6 months

Description: Measured with the Dietary Screener Questionnaire (NHANES 2009-10) to examine quality of participants' diet

Measure: Change from Baseline Diet at 4 Months

Time: Difference in diet between baseline and 4 months

Description: Measured with the Dietary Screener Questionnaire (NHANES 2009-10) to examine quality of participants' diet

Measure: Change from Baseline Diet at 6 Months

Time: Difference in diet between baseline and 6 months

Description: Measured using the Centers for Disease Control and Prevention Behavioral Risk Factor Surveillance Survey Physical Activity Module

Measure: Change from Baseline Physical Activity (PA) at 4 Months

Time: Difference in PA between baseline and 4 months

Description: Measured using the Centers for Disease Control and Prevention Behavioral Risk Factor Surveillance Survey Physical Activity Module

Measure: Change from Baseline Physical Activity (PA) at 6 Months

Time: Difference in PA between baseline and 6 months

Description: Well-being and general health measured with Short Form-36v2; There are 8 sections each scored 0-100 with a high score indicating less disability

Measure: Change from Baseline Health-Related Well-being at 4 Months

Time: Difference in health-related well-being between baseline and 4 months

Description: Well-being and general health measured with Short Form-36v2

Measure: Change from Baseline Health-Related Well-being at 6 Months

Time: Difference in health-related well-being between baseline and 6 months

HPO Nodes


HP:0001824: Weight loss
Genes 337
NABP1 PTPN22 MC2R NOS1 LMNA DNAJC13 GALC IGH HSPG2 RPS20 NPM1 HLCS VPS35 ZBTB16 RHBDF2 CUL4B CDKN2C EWSR1 VHL SLC39A4 SDHD POU6F2 RRM2B SIGMAR1 FANCM SCNN1A IKZF1 PRNP AKT1 TP53 MALT1 KCNJ11 ATM IL6 MPL TCF4 PALB2 GALT IL12B TSHR HLA-DPA1 KRT10 EPCAM JAK2 EDN3 TP53 CFTR IL10 RAD51C NAB2 POLG FANCE GCK REST TGFBR2 KRT1 B2M TGFB1 SDHD GBA IGH SCNN1B CHEK2 H19 ATRIP DCTN1 BCOR SDHB GATA4 SLC9A6 FANCC SNCA TRAIP RARA BRIP1 PIK3R1 MEN1 ERCC3 TXNRD2 CACNA1S RB1 ERCC4 NRTN BRCA1 MPL PTEN CDKN2A PIK3CA PMS1 CDKN2B CCND1 FANCG BRCA2 HLA-DPB1 POLG MLX TRIP13 AVP PMS2 FOXP3 MST1 SLC22A4 CBL DLST COL12A1 BRCA2 TTR MAFB PLA2G6 SRSF2 TRIM28 DNMT3A EDNRB RBBP8 THPO PCNT SDHAF1 CRLF1 KDSR STAT5B SCNN1G SDHB CTLA4 ECE1 EPAS1 TET2 MRAP SPG11 COL6A2 SNCA CDH23 SUCLA2 GBA DAXX MLH1 BCL2 DIS3L2 FOXP1 KRAS IL23R STAT3 SLC6A8 PRKAR1A RRM2B TYMP FANCD2 RNF168 ERCC2 EIF4G1 LRRK2 SMAD4 GNPTAB IGH NDP NBN LPIN2 MAD2L2 NF1 SDHAF2 HLA-DQB1 CENPJ FANCL CALR FANCB WT1 UNC80 FAN1 PRTN3 TET2 VPS13A NOD2 HLA-B SEMA3D PRNP SDHD SLX4 SDHD GJA1 GIGYF2 TLR4 PRNP FLI1 GJB3 ABCC8 TP53 TSHR GATA2 SDHC BRCA2 STAR SEMA4A SDHA IRF2BP2 PALB2 TET2 IFNGR1 BRCA1 ASXL1 PSAP GJB4 CACNA1S KIF1B TRPV4 STAT3 FANCF RET PTEN LMNA ALS2 KCNJ18 UBE2T KRAS JAK2 ACAT1 STAT4 PTEN HLA-DRB1 ACADM C4A EIF2AK3 TMEM127 RUNX1 ZMPSTE24 MAX CCND1 CCR1 MDH2 HTT UBAC2 BTK SLC2A3 MSH6 HFE BIRC3 UNC80 MEFV TP53 BMPR1A PLK4 PALLD FAS MECP2 HLA-DQB1 BCL10 ERCC4 BCL6 NUMA1 PADI4 RAD51 JAK2 SCNN1G MSH2 F5 XRCC2 CNTNAP1 PDX1 FANCI COL6A3 ERAP1 SDHC POLG CDC73 JAK2 HLA-DRB1 PTPN22 KIF1B PML TRIM28 FIP1L1 MLH3 STAT6 RFWD3 HTT HAVCR2 HMGCL TBL1XR1 RET FH KLRC4 PTPN22 ERCC4 HLA-B KCNJ18 BMPR1A HLA-DRB1 SDHB MPL ATRX ATP7B AK2 IL10 FANCA VHL HLA-DRB1 LRP12 TRIM37 GABRA3 IL12A-AS1 SCNN1A GPC3 NNT SCNN1B TYMP CDKN1B DCTN1 ATR GPR35 CIITA HLA-DQA1 NOD2 CDKN1A CENPE FUS WT1 SLC25A11 RET JPH3 SDHB JPH3 IL12A WT1 CD244 LIPA CEP152 SLC11A1 COL6A1 GDNF ERCC5 SEMA3C NFKBIL1 BTNL2 NALCN INS HLA-B CYP24A1 PANK2 SDHA
Protein Mutations 2
I148M P12A
HP:0004325: Decreased body weight
Genes 1864
RPS7 TRNK TRAIP MAGEL2 SIX2 B3GLCT TOP3A NDUFS4 DOLK SCNN1G CD247 CNKSR2 ATP6V1A PSAT1 ARVCF RPS15A ND1 RELB RREB1 PTF1A MALT1 OCA2 LETM1 DEGS1 ELMO2 ERMARD PEX11B SPATA5 KRT10 TERT AARS1 AGPS ZAP70 ZIC3 POLG CDC45 DMD FOXH1 LAMB3 COL1A2 BRIP1 SGO1 ABCC8 VPS13B PIK3R1 HSD3B7 BRAF PNPO SEC24C ERCC1 PIK3CA HCN1 NUP62 PEX13 ATP5F1A FANCG NDUFV2 INS EVC2 MCCC2 GPT2 DLST ATP6V0A2 MDH2 TPM2 MCEE COL6A1 DNMT3A SIN3A THPO CRLF1 KRAS VPS45 KMT2A CLCNKA SLC25A24 VPS13B KRT14 TPM2 PLAGL1 FOXP1 DALRD3 GK CD79A RRM2B MTO1 IGF2 ATP6V1E1 PEX19 MAP2K2 CR2 PPP1R15B SDHA CNOT1 ACTL6B SNORD115-1 MADD FANCL NDUFB11 CPLX1 KCNB1 ALOXE3 MKRN3-AS1 PRKAR1A ACADVL FAN1 COX10 TET2 RFX5 SEMA3D HRAS GJA1 NGLY1 GLI2 PCSK1 AGPAT2 KIAA0753 PREPL SCO2 PUF60 FANCF PWRN1 WDR11 ND4 RPS19 PNKP IGF2 DLL4 MBTPS2 DISP1 SIX3 PEX7 TRNN SLC19A3 LHX4 SCO1 BTK MSH6 PEX13 SLC39A4 GK NDUFB11 TTN RET RBCK1 ZIC2 TIMM22 WDFY3 PSMB9 CSF2RA UMPS SMAD4 ERCC2 LAMA2 GABRA2 FGF8 GCK TCOF1 SHH CNTNAP1 SLC22A5 SYNGAP1 HACD1 CREBBP OCA2 NODAL NOTCH2 SKI MRPS14 SLC9A6 RAD21 SMARCA2 CLMP ADAT3 ECHS1 DLL1 RFXAP CASK TCTN3 PTPN22 SLC6A8 FGF12 TRNS2 CKAP2L NLRP1 TIMMDC1 PPM1B IL10 COG4 MARS1 SIK1 ETHE1 SSR4 RPS19 CDKN1C TBC1D23 IL12A-AS1 CIT TYMP CDKN1B SLC13A5 CYP2R1 LPIN2 FGFR1 CENPE NDUFS4 TACO1 FDFT1 JPH3 IRF6 CNKSR2 CARS1 IL21R SAR1B GDNF USP9X PEX1 TCF20 EXOSC9 CYB5A GALC DDOST CUL4B AUTS2 DYNC2LI1 EWSR1 VHL POU6F2 EBP PMM2 SIGMAR1 FBN2 FBN1 CNTNAP2 NDN RAG2 PEX5 SPOP PGM3 FANCE MPL MYOD1 NDUFS6 TSHR EDN3 XPA BCAP31 WWOX SYNJ1 STT3A HCCS GBA PARN NDP PPP1R15B PSMD12 DCTN1 LAMC2 RAG2 SLC9A6 GNPAT DCLRE1C FANCC SNCA PYGL PDHX CAMKMT HPD MED12 AMACR MCCC1 TWNK STAT5B CYP11B2 CD3D RIT1 IL2RB CACNA1S GLI2 RNU4ATAC MGAT2 NRTN COL6A3 TASP1 TIMM50 PMS1 IL7R BRCA2 TTC37 MLX AVP MCTP2 IGLL1 FGFR1 TK2 MAGEL2 SYP PLA2G6 TPM3 SYNE1 COL12A1 PEX16 PCNT IQSEC2 SDHB MUSK HYMAI BRCA1 BUB1B INSR NDUFA1 COL1A1 RPS6KA3 PTPRC NPHS1 SLC6A8 FOXH1 CPS1 NDUFA2 PRKAR1A GPIHBP1 FGD1 SNX10 COX3 COG8 NDUFV2 LRRK2 USF3 GNPTAB TFAM HADHB MTTP H19 NBN LARP7 STRA6 NUP188 NDUFAF3 NDUFAF2 CRIPT FANCB CD3D UNC80 PEX2 PEX10 PUS7 CLCNKB PIGB TAF13 SLC25A13 HMGA2 TCN2 SLC2A2 UBTF RPL31 AQP2 WDR26 UBA1 ABCC8 TP53 BRCA2 PALB2 BSND GAS1 NDUFAF2 SAMD9 PSAP ERCC5 STAT3 KBTBD13 ARMC5 PLAG1 JAK2 NFKB1 IL1RN TMEM126B ACADM TRAK1 RYR1 FUT8 PEX12 ALOX12B MDH2 HADHA NFKB2 HIBCH SLC34A3 TGIF1 SELENON IGF2 EMG1 DKC1 TDGF1 PRKACA KRT6A ALB NFASC POLG PEX5 CDC73 TSR2 POLR1A CTNS SIX3 PML GTF2E2 POLR1C KRT6B FH FOS RBM10 ORC1 BMPR1A DPM1 NAT8L MYH3 NFKB2 HSD3B7 VHL ALDH18A1 PEX11B TRIM37 SDHD TLL1 SLC12A1 PPARG DCLRE1C SCNN1A MCM9 GPC3 DCTN1 ALG9 CYP11B2 NOD2 KRAS CYP27B1 LTC4S NTNG1 IL2RG IL7R SLC17A5 SDHB SMPD1 GATM JPH3 NODAL SPRTN NR1H4 SEMA3C NONO NALCN PSMB4 NOS1 UBR1 ND6 PEX6 ARHGAP31 MS4A1 NODAL COX20 POLA1 VPS35 DHCR7 ZNF711 NECAP1 CASP8 CAVIN1 TACR3 SDHD ASXL1 IFNG ARX RRM2B EIF2S3 JAK3 ZNF335 ATP6V1E1 ATM CTBP1 KCNJ6 HADHA MEGF10 ARX HUWE1 ACTA1 TP53 IGF2 NAB2 FGF8 PEX13 GAS1 BMP4 CHEK2 CPLANE1 ELN FANCD2 RAG1 MYT1L PIK3R1 GP1BB NFU1 PMM2 TPM2 DLL1 TXNRD2 CCNQ RB1 PTEN PDHB CLTC NDUFAF5 ORC4 NOTCH1 PMS2 ABCA12 RPL27 SEC23B CDON ADAR TCF3 SLC3A1 GDI1 CA2 RBBP8 PTCHD1 SDHAF1 STAT5B CREBBP TBL1XR1 NPAP1 SOX9 SLC7A7 BCS1L SCN3A DOCK6 TWIST2 BCL2 DIS3L2 KRAS PHOX2B CDK19 NDUFB8 KMT2E BANF1 FANCD2 HPD IFIH1 IL7R PUS3 CIITA ZIC2 G6PC3 NDUFB10 DNAJC21 PEX26 DISP1 IL2RA DNA2 PEX19 NCAPG2 FOXH1 YWHAG PNP BAAT MRPL3 PRTN3 SP110 MED13 TRNS1 FZD4 DNMT3A ACD SKIV2L NADK2 FANCI GRIA4 ZAP70 ALDOB ZNF81 ND2 SMARCC2 ND5 BRCA1 RPS6KA3 FGFRL1 USP8 GCDH LMNA ALS2 CDK10 PEX3 INSR OTC CDC45 C4A ACO2 TRNQ DNAJC21 ZMPSTE24 RAI1 VPS37A MECP2 SNRPN SON RAB33B SBDS PNPLA6 CYP7B1 PEX1 SLC25A15 CHRM3 DMXL2 EPRS1 GRIN2D TP53 PLK4 BCL10 PRF1 RAG2 JAK2 CD40LG MSH2 TRMT10C MMACHC KIAA0586 HADHB SDHB AMER1 KIF7 MYH3 PTPN22 FOXP3 CEP57 AKT1 TRNF THOC2 NUS1 RAG1 SARS1 STAT6 KANSL1 HAVCR2 HMGCL PEX16 SLC4A1 TBL1XR1 IL2RG DNM1 SDHB ZFP57 CARS2 PLAA OFD1 KLHL7 CDON LRRC8A RPL26 COG1 LRP5 RMRP ACTG1 NNT OTUD6B EARS2 KDM6A STRADA ANAPC1 PWAR1 TCF4 CTCF ERCC4 SCN8A ASNS FAM111A FBN1 SCNN1A ACTA1 PEX16 NIPBL SMAD4 POMP LIPT1 TRNL1 FGFR1 CHD7 PTPN22 TBR1 NNT SRP54 SPRY4 CDKN2C NDUFA10 TGDS CCDC47 ND2 ADAT3 RPS17 KIF7 SCNN1A PRNP B3GALT6 TP53 YARS2 PDE11A CREBBP NDUFS7 PDE6D ATP6V1A TBX1 XYLT2 TNFSF12 UBE3B EPCAM MECP2 IL10 ABL1 PIK3CA NDUFS8 COPB2 GCK EHMT1 PDX1 CTNS SDHD STRADA NDUFAF5 NDUFB11 FOXP1 FUCA1 BCOR SDHB NDUFS1 PPP2R3C NSD2 CYP2R1 FH ARFGEF2 KISS1 TRAIP PEX5 PDHA1 SFTPC B3GALT6 ATP6V1A ERCC4 NADK2 CSF2RB MPL ARV1 ABCA3 FAM149B1 CCND1 ASL FCGR2A AVPR2 NEUROD2 TRIM28 ZNF41 SSR4 ALG8 CD79A PIK3R1 PIGP DDX3X TRNS1 KDSR STEEP1 SCNN1G ASXL3 MAP2K1 MKKS ECE1 RNF13 ESR2 SAR1B SC5D SUCLA2 GBA IL23R COX2 RTL1 TRAK1 PEX12 HADH RASGRP1 FGF8 SNRPN EPHX1 GBE1 NDP STT3B TCF4 TIMMDC1 LMNA TCTN3 SDHD HIKESHI SLC25A13 TDGF1 SLC5A1 GIGYF2 LRPPRC GJB3 ACOX1 SDHA PPP3CA PEX26 GNB1 DYRK1A NDUFS1 MYH7 NSMCE3 PTEN TGIF1 PCLO KRAS GTF2I SCN2A ATP6V0A4 CYFIP2 KCNA2 TMEM127 FTO KCNJ11 JAGN1 CIITA GMNN SETD5 ZSWIM6 CSPP1 CCR1 PLEC NFIX GPR161 DYRK1A ELAC2 EFL1 PNPLA1 HMGA2 FAS UPF3B MBTPS1 SLC10A2 RAD51 ANTXR2 DHDDS AARS2 TSHR OTUD6B POMC TGFB1 NDUFA9 HCFC1 MMUT XRCC2 COL6A3 ERAP1 ERCC6 FARSB JAK2 SLC3A1 OBSL1 GBA SLC25A22 LETM1 COX4I1 SLC25A3 TBX4 HERC2 RFWD3 IGF2 KLRC4 PREPL DLK1 MLXIPL VIPAS39 IQSEC2 HLA-DRB1 MPL ALG12 AK2 ANOS1 NKX2-1 GNAO1 TMPRSS15 GPR35 BAZ1B CIITA TRAPPC4 MED12 CDKN1A WT1 GRIA3 MIPEP NDUFB3 PEX1 ARHGEF6 BRCA2 RNU4ATAC ERCC2 TGFB3 LAMA3 KCNAB2 FGF17 CTNS COL6A1 TRIO SPR ERCC5 NFKBIL1 PYGL ADAM17 DISP1 ANKLE2 UBE3B SLC26A3 ACSF3 CYP11B2 UBR1 EEF1A2 PET100 LMNA PROK2 KCNA1 NFE2L2 PEX3 HSPG2 LCK ACTB IARS1 ERCC6 MAGEL2 SLC25A13 NDUFAF4 GTF2IRD1 CAVIN1 SLC9A7 CHD7 FRMPD4 NHLRC2 NGLY1 STAG1 FANCM NOTCH2 PACS1 NELFA FDXR KCNJ11 GLI1 STXBP1 TGM1 ASS1 EXT1 TCF4 AIMP1 HLA-DPA1 KRT16 SETBP1 PIEZO2 GPC1 EBP SIM1 GNPTAB TJP2 NACC1 SDHA CDC6 HBA1 PHGDH RARA ACTL6B ATP6V0A2 STT3B CD81 POLG2 FIG4 NR0B1 MTHFR CD96 ERCC8 HLA-DPB1 DLD TERT PEX2 FOXH1 CLCN4 GABRA5 SURF1 BRF1 SLC22A4 MECP2 COL12A1 SERAC1 ALAD FGFR1 TRMT10A LMBRD1 SLC1A2 PQBP1 PTRH2 KMT2A GAS1 DLK1 GJA1 GMNN ACTB TRNW NEB CTLA4 EPAS1 MRAP COL6A2 ERCC3 CBS SNCA COG8 CDH23 LIG4 BLM PPP3CA CDON TINF2 ADA2 KCNJ1 RAG1 VPS51 ERCC2 DISP1 NDUFAF6 FLNA FAH CYP27B1 GALC MAP3K20 NF1 SIL1 DNMT3B RPL35 SDHAF2 CENPJ NAGS RTTN TCIRG1 CALR GNRHR TDGF1 TAPT1 TMEM216 FTSJ1 RFT1 COX15 SDHD SLC35A2 FGF8 CDC6 FLI1 DPYD HBA2 ERCC2 SDHC WDR4 CFTR TFRC GJB4 KIF1B ROBO1 GTPBP2 KMT2A MTRR CYB5R3 ORC4 DNM2 IPW ASCL1 ATXN7 GATA6 KCNJ18 AUH RMRP STAG2 UQCRFS1 KCNA2 MAX BMPR1A RYR1 IGHM HTT SLC25A15 NEUROG3 UNC80 MEFV SUCLA2 PALLD PTDSS1 NDUFAF8 MSX1 AHCY ATPAF2 FANCC POLR3A BCL6 SKIV2L PADI4 CA12 ALG3 CASK FANCI FAM111A NDUFS2 SDHC NDUFS1 HBB UBA5 MMAA CNTN1 PEX6 SELENON TRIM28 ZIC2 HTT SBDS RET CPLANE1 CYP11A1 KDM6A NDUFS2 DHDDS TUBB4A PEX14 CYP19A1 ZFP57 MAGEL2 ETHE1 FANCA NSDHL GABRA3 KLLN SCNN1B CSF2RA FBXW11 PTCH1 EPG5 GLI2 LBR PPP1CB ARID1B BCOR IL12A CEP152 MMUT CLDN16 POLG2 ALG11 XPC PMPCB MKRN3 CD96 MYH7 JAK3 DNAJC21 MPI BRAF RHBDF2 WRN TGFB1 LYRM7 NDUFB9 RPS26 SLC39A4 PROKR2 POLE CDH23 SFTPB FANCF THRB CACNA1A PEX10 SLC46A1 JAK1 RAI1 JMJD1C PALB2 GALT SHROOM4 NRXN1 IL12B COQ7 OCLN UFC1 TBX1 STAMBP COX4I2 RFXANK PEX12 KAT6B KRT1 B2M CORIN TIMM50 NR3C2 PLAA MADD KLHL41 LIMK1 PEPD MYT1L RPL5 HMGA2 GTPBP3 CNOT1 NDUFAF1 ERCC3 EP300 CDKN2A NDUFA6 MCCC1 DCLRE1C CDKL5 RPS10 POLG NDUFS2 MAP3K7 VAC14 ND3 RBBP8 BPTF SIN3A GNB1 BRCA2 NSUN2 BRAF EDNRB IGHM SLC39A8 PYCR1 PNPO DEAF1 NSDHL KRT5 PSMD12 CD3E INTU MLH1 CENPJ STAT3 BPTF TYMP ORC6 CUL7 RNF168 CD3G RARS2 LONP1 TMEM126B GRIN2D ARCN1 SUCLG1 ACAD9 HESX1 AMPD2 IGH POLG LPIN2 SLC12A3 GYS2 TGIF1 ADA SETBP1 DUSP6 MBL2 ZMIZ1 HLA-B SLX4 CYP17A1 MPDU1 CDT1 GOT2 RECQL4 ATP6V0A2 LEMD3 GABRD TSHR ITCH SEMA4A IRF2BP2 TRMT5 EHMT1 ASXL1 TRIM8 RPL5 RPS27 DOCK3 SURF1 RPS24 TRPV4 VPS33B RPL35A RET MC2R UFD1 ASAH1 HNRNPH2 UBE2T SRP54 GBA CHRNG CDT1 LAMB3 ERCC6 MMAB KANSL1 PTCH1 EIF2AK3 RECQL4 TDGF1 TALDO1 RAI1 HFE NDUFS2 LAT STXBP1 ZEB2 HLA-DQB1 SMC1A MAP2K1 ABCC8 PCCB NDUFAF4 ERCC4 OCRL SMC3 COG1 ARPC1B PDX1 PEX19 GATA1 DLL1 RBPJ MRPS7 SHH TPM3 H19-ICR SARS2 MTRR MYL2 HDAC8 MLH3 STAG2 TBL1XR1 ALG13 EFL1 AQP2 STT3A DNAJC3 KMT2C LIG4 ATP7B LRP12 SNAP29 SCN3A AHDC1 PQBP1 PLP1 ABCC8 FANCA DSP CYP7B1 ATR DLL1 COMT PRKCD BLNK AGTPBP1 WT1 LIPA RAG2 ADA ERCC4 RPS6KA3 SELENON AUTS2 CYTB SALL1 BTNL2 IGF1 GRIA3 CYP24A1 TGIF1 IGH ALG13 ACADS YY1AP1 NPM1 ATP6V0A2 ZBTB16 AGTR2 AHCY INSR COL7A1 MCM5 DDB2 CASK RTL1 SHH TUBB4A GABRG2 EGFR OSGEP LAMA3 IKZF1 ACSF3 YY1 HYMAI PIK3C2A AKT1 LMBRD1 AARS1 SCNN1B GALT GAA NEB PARN MRPS2 PNPT1 PTEN CASR RAB3GAP1 NDN RAD51C MPV17 GALE RAB39B PRDX1 REST TGFBR2 PRPS1 MTR IGH CLIP2 SCNN1B H19 TAZ IGF1R HIRA GNAS SVBP MEN1 COX1 HSD17B4 SIX3 FOXG1 PTF1A ELN MCCC2 GNRH1 CLCNKB PET100 ACTB FOXP3 ND4 IGHMBP2 PTS CBL SLC39A13 POLA1 TTR SON MAFB RPL11 GABRB2 PAM16 TET2 SPG11 HPDL PEX2 PCCA TTC37 DACT1 DAXX POLR1D NTRK2 KRT14 RPL15 SHH PKP1 TRNV TANC2 NUS1 SLC12A3 GHSR TRAC RNF13 OCRL IL21 SLC25A4 NDUFA11 NDUFS3 GBA TSPAN7 SLC35C1 HRAS C12ORF65 VPS13A EXT2 NOD2 NDUFA12 ADK GRIN2A TRNH RAG1 ORAI1 AGXT SNRPN TGFB1 PTPN11 PDE8B FGFR1 GATA2 IGF1 STAR MSMO1 TRMT1 ORC6 IFNGR1 SLC7A7 CACNA1S RARB GATA6 ND1 KMT2D WDR73 TKFC FOXRED1 LIPA MICOS13 ACAT1 TMEM216 STING1 PAK3 SUGCT FLNA DALRD3 HLA-DRB1 ZEB2 TNFRSF13C RPL18 AP1B1 CHRNA3 CCND1 KRT5 MRPS28 SLC2A3 PLP1 KIF15 ADA FIG4 MECP2 FLNA ND3 NUMA1 PDHA1 SCNN1G FBXL4 ASXL1 LARS1 F5 MED17 NSD2 HLA-DRB1 AP3B2 DDX6 KIF1B PTCH1 WNT2B ORC1 NDUFV1 FMR1 INS CYP11A1 ERCC4 CDON ST3GAL5 POLR3A GPT2 CCDC8 NDUFA13 BCORL1 SMOC1 NDUFA4 ATRX ACSL4 ND1 COG7 COG4 MID2 SLC34A1 HSD11B2 STAG2 ANOS1 NDUFAF3 PYCR2 HLA-DQA1 NACC1 RBM10 TP63 NUP214 FGF8 PDX1 GLYCTK CD244 PEX14 KANSL1 TNFSF12 NIPAL4 SLC11A1 NDUFS3 DGAT1 RPS28 NDN WDR11 SLC25A21 PANK2 MRPS16 C12ORF65 RAI1 NABP1 MC2R BSCL2 DPM2 NAGS BMP1 OCA2 MYMK PCGF2 FLCN DNAJC13 CAV1 BCAP31 DYRK1A RPS20 HLCS CYP17A1 NONO LAMC2 IL1RAPL1 NALCN ITCH ATM PTRH2 LYRM4 POLG NDUFS8 NDUFB8 IL6 RECQL4 NECTIN1 COL6A2 RAC2 JAK2 ATP8B1 TBL2 CFTR AKR1D1 EVC HERC1 DNM1L TAC3 METTL5 FANCE POC1A TGFB1 NEXMIF CSNK2A1 ATRIP MEG3 RFC2 GATA4 SNORD116-1 TMEM165 POLR2A NDUFAF5 RRM2B NEB TPM3 WDR4 FLT1 CD19 SURF1 EPCAM SIX3 SMARCD2 BRCA1 SELENON PSMB8 CDKN2B SZT2 HS6ST1 TRIP13 DNA2 MST1 CERS3 MRPL12 MMACHC CDON B4GALT7 SRSF2 NUP62 SMC1A FOXRED1 MEG3 AVPR2 MED12 CACNA1B COG6 CD79B LMNA PRDM16 STOX1 ASAH1 ACTL6A NDUFS7 MYPN ZIC2 ITGA7 NUBPL TRIT1 HADHA USP27X ACTA1 SPINK5 NDUFB3 EIF4G1 KCNJ6 SMAD4 DYNC2I1 ACTA1 HBB RERE MAD2L2 SKI HLA-DQB1 PLAG1 PIK3CA POR PGM3 ABCB11 EOGT WT1 PUS1 TRNW SMC1A SLC46A1 MTFMT ICOS PRNP RTTN RFX5 SDHC DCLRE1C SEC31A TLR4 COX7B PTCH1 IL2RG PRNP GLI2 PDHA1 OTULIN GAS1 TNFRSF13B TET2 NDUFA13 NDUFV1 RFXAP CARMIL2 CREB3L1 DPP6 MAGEL2 DGUOK STAT4 KISS1R PTEN H19 RUNX1 CYB5A RIPK1 NSMF MOGS UBA5 MYH3 UBAC2 MAP2K1 RIN2 BIRC3 SCN1B IKBKB PARS2 BMPR1A MMADHC NLRC4 KCNA4 NDN TMEM70 EXOSC8 DHCR24 SLC25A24 KRT17 ALPL AUH TRNL1 RET TRMT1 PEX5 SNRPN JAG1 ACVR1 FIP1L1 NDUFV2 ND5 NFIX CENPT WHCR DLG3 RFXANK ND6 HLA-B EP300 DDOST KCNJ18 MAGEL2 NDUFS4 AHDC1 HCFC1 HLA-DRB1 RPS29 NODAL GRM7 LRBA VDR ATP6 ERCC4 PYCR2 NDUFAF1 FUS RFT1 PROKR2 USP7 SLC25A11 RET FLII ATP6 DHCR24 RTEL1 HSD11B2 COA8 CLTCL1 KCNJ11 RLIM PIGQ ITGB4 INS HLA-B SDHA MVK
Protein Mutations 0
SNP 0

HPO

Alphabetical listing of all HPO terms. Navigate: Correlations   Clinical Trials


HPO Nodes


HP:0001824: Weight loss
Genes 337
NABP1 PTPN22 MC2R NOS1 LMNA DNAJC13 GALC IGH HSPG2 RPS20 NPM1 HLCS VPS35 ZBTB16 RHBDF2 CUL4B CDKN2C EWSR1 VHL SLC39A4 SDHD POU6F2 RRM2B SIGMAR1 FANCM SCNN1A IKZF1 PRNP AKT1 TP53 MALT1 KCNJ11 ATM IL6 MPL TCF4 PALB2 GALT IL12B TSHR HLA-DPA1 KRT10 EPCAM JAK2 EDN3 TP53 CFTR IL10 RAD51C NAB2 POLG FANCE GCK REST TGFBR2 KRT1 B2M TGFB1 SDHD GBA IGH SCNN1B CHEK2 H19 ATRIP DCTN1 BCOR SDHB GATA4 SLC9A6 FANCC SNCA TRAIP RARA BRIP1 PIK3R1 MEN1 ERCC3 TXNRD2 CACNA1S RB1 ERCC4 NRTN BRCA1 MPL PTEN CDKN2A PIK3CA PMS1 CDKN2B CCND1 FANCG BRCA2 HLA-DPB1 POLG MLX TRIP13 AVP PMS2 FOXP3 MST1 SLC22A4 CBL DLST COL12A1 BRCA2 TTR MAFB PLA2G6 SRSF2 TRIM28 DNMT3A EDNRB RBBP8 THPO PCNT SDHAF1 CRLF1 KDSR STAT5B SCNN1G SDHB CTLA4 ECE1 EPAS1 TET2 MRAP SPG11 COL6A2 SNCA CDH23 SUCLA2 GBA DAXX MLH1 BCL2 DIS3L2 FOXP1 KRAS IL23R STAT3 SLC6A8 PRKAR1A RRM2B TYMP FANCD2 RNF168 ERCC2 EIF4G1 LRRK2 SMAD4 GNPTAB IGH NDP NBN LPIN2 MAD2L2 NF1 SDHAF2 HLA-DQB1 CENPJ FANCL CALR FANCB WT1 UNC80 FAN1 PRTN3 TET2 VPS13A NOD2 HLA-B SEMA3D PRNP SDHD SLX4 SDHD GJA1 GIGYF2 TLR4 PRNP FLI1 GJB3 ABCC8 TP53 TSHR GATA2 SDHC BRCA2 STAR SEMA4A SDHA IRF2BP2 PALB2 TET2 IFNGR1 BRCA1 ASXL1 PSAP GJB4 CACNA1S KIF1B TRPV4 STAT3 FANCF RET PTEN LMNA ALS2 KCNJ18 UBE2T KRAS JAK2 ACAT1 STAT4 PTEN HLA-DRB1 ACADM C4A EIF2AK3 TMEM127 RUNX1 ZMPSTE24 MAX CCND1 CCR1 MDH2 HTT UBAC2 BTK SLC2A3 MSH6 HFE BIRC3 UNC80 MEFV TP53 BMPR1A PLK4 PALLD FAS MECP2 HLA-DQB1 BCL10 ERCC4 BCL6 NUMA1 PADI4 RAD51 JAK2 SCNN1G MSH2 F5 XRCC2 CNTNAP1 PDX1 FANCI COL6A3 ERAP1 SDHC POLG CDC73 JAK2 HLA-DRB1 PTPN22 KIF1B PML TRIM28 FIP1L1 MLH3 STAT6 RFWD3 HTT HAVCR2 HMGCL TBL1XR1 RET FH KLRC4 PTPN22 ERCC4 HLA-B KCNJ18 BMPR1A HLA-DRB1 SDHB MPL ATRX ATP7B AK2 IL10 FANCA VHL HLA-DRB1 LRP12 TRIM37 GABRA3 IL12A-AS1 SCNN1A GPC3 NNT SCNN1B TYMP CDKN1B DCTN1 ATR GPR35 CIITA HLA-DQA1 NOD2 CDKN1A CENPE FUS WT1 SLC25A11 RET JPH3 SDHB JPH3 IL12A WT1 CD244 LIPA CEP152 SLC11A1 COL6A1 GDNF ERCC5 SEMA3C NFKBIL1 BTNL2 NALCN INS HLA-B CYP24A1 PANK2 SDHA
Protein Mutations 2
I148M P12A
HP:0004325: Decreased body weight
Genes 1864
RPS7 TRNK TRAIP MAGEL2 SIX2 B3GLCT TOP3A NDUFS4 DOLK SCNN1G CD247 CNKSR2 ATP6V1A PSAT1 ARVCF RPS15A ND1 RELB RREB1 PTF1A MALT1 OCA2 LETM1 DEGS1 ELMO2 ERMARD PEX11B SPATA5 KRT10 TERT AARS1 AGPS ZAP70 ZIC3 POLG CDC45 DMD FOXH1 LAMB3 COL1A2 BRIP1 SGO1 ABCC8 VPS13B PIK3R1 HSD3B7 BRAF PNPO SEC24C ERCC1 PIK3CA HCN1 NUP62 PEX13 ATP5F1A FANCG NDUFV2 INS EVC2 MCCC2 GPT2 DLST ATP6V0A2 MDH2 TPM2 MCEE COL6A1 DNMT3A SIN3A THPO CRLF1 KRAS VPS45 KMT2A CLCNKA SLC25A24 VPS13B KRT14 TPM2 PLAGL1 FOXP1 DALRD3 GK CD79A RRM2B MTO1 IGF2 ATP6V1E1 PEX19 MAP2K2 CR2 PPP1R15B SDHA CNOT1 ACTL6B SNORD115-1 MADD FANCL NDUFB11 CPLX1 KCNB1 ALOXE3 MKRN3-AS1 PRKAR1A ACADVL FAN1 COX10 TET2 RFX5 SEMA3D HRAS GJA1 NGLY1 GLI2 PCSK1 AGPAT2 KIAA0753 PREPL SCO2 PUF60 FANCF PWRN1 WDR11 ND4 RPS19 PNKP IGF2 DLL4 MBTPS2 DISP1 SIX3 PEX7 TRNN SLC19A3 LHX4 SCO1 BTK MSH6 PEX13 SLC39A4 GK NDUFB11 TTN RET RBCK1 ZIC2 TIMM22 WDFY3 PSMB9 CSF2RA UMPS SMAD4 ERCC2 LAMA2 GABRA2 FGF8 GCK TCOF1 SHH CNTNAP1 SLC22A5 SYNGAP1 HACD1 CREBBP OCA2 NODAL NOTCH2 SKI MRPS14 SLC9A6 RAD21 SMARCA2 CLMP ADAT3 ECHS1 DLL1 RFXAP CASK TCTN3 PTPN22 SLC6A8 FGF12 TRNS2 CKAP2L NLRP1 TIMMDC1 PPM1B IL10 COG4 MARS1 SIK1 ETHE1 SSR4 RPS19 CDKN1C TBC1D23 IL12A-AS1 CIT TYMP CDKN1B SLC13A5 CYP2R1 LPIN2 FGFR1 CENPE NDUFS4 TACO1 FDFT1 JPH3 IRF6 CNKSR2 CARS1 IL21R SAR1B GDNF USP9X PEX1 TCF20 EXOSC9 CYB5A GALC DDOST CUL4B AUTS2 DYNC2LI1 EWSR1 VHL POU6F2 EBP PMM2 SIGMAR1 FBN2 FBN1 CNTNAP2 NDN RAG2 PEX5 SPOP PGM3 FANCE MPL MYOD1 NDUFS6 TSHR EDN3 XPA BCAP31 WWOX SYNJ1 STT3A HCCS GBA PARN NDP PPP1R15B PSMD12 DCTN1 LAMC2 RAG2 SLC9A6 GNPAT DCLRE1C FANCC SNCA PYGL PDHX CAMKMT HPD MED12 AMACR MCCC1 TWNK STAT5B CYP11B2 CD3D RIT1 IL2RB CACNA1S GLI2 RNU4ATAC MGAT2 NRTN COL6A3 TASP1 TIMM50 PMS1 IL7R BRCA2 TTC37 MLX AVP MCTP2 IGLL1 FGFR1 TK2 MAGEL2 SYP PLA2G6 TPM3 SYNE1 COL12A1 PEX16 PCNT IQSEC2 SDHB MUSK HYMAI BRCA1 BUB1B INSR NDUFA1 COL1A1 RPS6KA3 PTPRC NPHS1 SLC6A8 FOXH1 CPS1 NDUFA2 PRKAR1A GPIHBP1 FGD1 SNX10 COX3 COG8 NDUFV2 LRRK2 USF3 GNPTAB TFAM HADHB MTTP H19 NBN LARP7 STRA6 NUP188 NDUFAF3 NDUFAF2 CRIPT FANCB CD3D UNC80 PEX2 PEX10 PUS7 CLCNKB PIGB TAF13 SLC25A13 HMGA2 TCN2 SLC2A2 UBTF RPL31 AQP2 WDR26 UBA1 ABCC8 TP53 BRCA2 PALB2 BSND GAS1 NDUFAF2 SAMD9 PSAP ERCC5 STAT3 KBTBD13 ARMC5 PLAG1 JAK2 NFKB1 IL1RN TMEM126B ACADM TRAK1 RYR1 FUT8 PEX12 ALOX12B MDH2 HADHA NFKB2 HIBCH SLC34A3 TGIF1 SELENON IGF2 EMG1 DKC1 TDGF1 PRKACA KRT6A ALB NFASC POLG PEX5 CDC73 TSR2 POLR1A CTNS SIX3 PML GTF2E2 POLR1C KRT6B FH FOS RBM10 ORC1 BMPR1A DPM1 NAT8L MYH3 NFKB2 HSD3B7 VHL ALDH18A1 PEX11B TRIM37 SDHD TLL1 SLC12A1 PPARG DCLRE1C SCNN1A MCM9 GPC3 DCTN1 ALG9 CYP11B2 NOD2 KRAS CYP27B1 LTC4S NTNG1 IL2RG IL7R SLC17A5 SDHB SMPD1 GATM JPH3 NODAL SPRTN NR1H4 SEMA3C NONO NALCN PSMB4 NOS1 UBR1 ND6 PEX6 ARHGAP31 MS4A1 NODAL COX20 POLA1 VPS35 DHCR7 ZNF711 NECAP1 CASP8 CAVIN1 TACR3 SDHD ASXL1 IFNG ARX RRM2B EIF2S3 JAK3 ZNF335 ATP6V1E1 ATM CTBP1 KCNJ6 HADHA MEGF10 ARX HUWE1 ACTA1 TP53 IGF2 NAB2 FGF8 PEX13 GAS1 BMP4 CHEK2 CPLANE1 ELN FANCD2 RAG1 MYT1L PIK3R1 GP1BB NFU1 PMM2 TPM2 DLL1 TXNRD2 CCNQ RB1 PTEN PDHB CLTC NDUFAF5 ORC4 NOTCH1 PMS2 ABCA12 RPL27 SEC23B CDON ADAR TCF3 SLC3A1 GDI1 CA2 RBBP8 PTCHD1 SDHAF1 STAT5B CREBBP TBL1XR1 NPAP1 SOX9 SLC7A7 BCS1L SCN3A DOCK6 TWIST2 BCL2 DIS3L2 KRAS PHOX2B CDK19 NDUFB8 KMT2E BANF1 FANCD2 HPD IFIH1 IL7R PUS3 CIITA ZIC2 G6PC3 NDUFB10 DNAJC21 PEX26 DISP1 IL2RA DNA2 PEX19 NCAPG2 FOXH1 YWHAG PNP BAAT MRPL3 PRTN3 SP110 MED13 TRNS1 FZD4 DNMT3A ACD SKIV2L NADK2 FANCI GRIA4 ZAP70 ALDOB ZNF81 ND2 SMARCC2 ND5 BRCA1 RPS6KA3 FGFRL1 USP8 GCDH LMNA ALS2 CDK10 PEX3 INSR OTC CDC45 C4A ACO2 TRNQ DNAJC21 ZMPSTE24 RAI1 VPS37A MECP2 SNRPN SON RAB33B SBDS PNPLA6 CYP7B1 PEX1 SLC25A15 CHRM3 DMXL2 EPRS1 GRIN2D TP53 PLK4 BCL10 PRF1 RAG2 JAK2 CD40LG MSH2 TRMT10C MMACHC KIAA0586 HADHB SDHB AMER1 KIF7 MYH3 PTPN22 FOXP3 CEP57 AKT1 TRNF THOC2 NUS1 RAG1 SARS1 STAT6 KANSL1 HAVCR2 HMGCL PEX16 SLC4A1 TBL1XR1 IL2RG DNM1 SDHB ZFP57 CARS2 PLAA OFD1 KLHL7 CDON LRRC8A RPL26 COG1 LRP5 RMRP ACTG1 NNT OTUD6B EARS2 KDM6A STRADA ANAPC1 PWAR1 TCF4 CTCF ERCC4 SCN8A ASNS FAM111A FBN1 SCNN1A ACTA1 PEX16 NIPBL SMAD4 POMP LIPT1 TRNL1 FGFR1 CHD7 PTPN22 TBR1 NNT SRP54 SPRY4 CDKN2C NDUFA10 TGDS CCDC47 ND2 ADAT3 RPS17 KIF7 SCNN1A PRNP B3GALT6 TP53 YARS2 PDE11A CREBBP NDUFS7 PDE6D ATP6V1A TBX1 XYLT2 TNFSF12 UBE3B EPCAM MECP2 IL10 ABL1 PIK3CA NDUFS8 COPB2 GCK EHMT1 PDX1 CTNS SDHD STRADA NDUFAF5 NDUFB11 FOXP1 FUCA1 BCOR SDHB NDUFS1 PPP2R3C NSD2 CYP2R1 FH ARFGEF2 KISS1 TRAIP PEX5 PDHA1 SFTPC B3GALT6 ATP6V1A ERCC4 NADK2 CSF2RB MPL ARV1 ABCA3 FAM149B1 CCND1 ASL FCGR2A AVPR2 NEUROD2 TRIM28 ZNF41 SSR4 ALG8 CD79A PIK3R1 PIGP DDX3X TRNS1 KDSR STEEP1 SCNN1G ASXL3 MAP2K1 MKKS ECE1 RNF13 ESR2 SAR1B SC5D SUCLA2 GBA IL23R COX2 RTL1 TRAK1 PEX12 HADH RASGRP1 FGF8 SNRPN EPHX1 GBE1 NDP STT3B TCF4 TIMMDC1 LMNA TCTN3 SDHD HIKESHI SLC25A13 TDGF1 SLC5A1 GIGYF2 LRPPRC GJB3 ACOX1 SDHA PPP3CA PEX26 GNB1 DYRK1A NDUFS1 MYH7 NSMCE3 PTEN TGIF1 PCLO KRAS GTF2I SCN2A ATP6V0A4 CYFIP2 KCNA2 TMEM127 FTO KCNJ11 JAGN1 CIITA GMNN SETD5 ZSWIM6 CSPP1 CCR1 PLEC NFIX GPR161 DYRK1A ELAC2 EFL1 PNPLA1 HMGA2 FAS UPF3B MBTPS1 SLC10A2 RAD51 ANTXR2 DHDDS AARS2 TSHR OTUD6B POMC TGFB1 NDUFA9 HCFC1 MMUT XRCC2 COL6A3 ERAP1 ERCC6 FARSB JAK2 SLC3A1 OBSL1 GBA SLC25A22 LETM1 COX4I1 SLC25A3 TBX4 HERC2 RFWD3 IGF2 KLRC4 PREPL DLK1 MLXIPL VIPAS39 IQSEC2 HLA-DRB1 MPL ALG12 AK2 ANOS1 NKX2-1 GNAO1 TMPRSS15 GPR35 BAZ1B CIITA TRAPPC4 MED12 CDKN1A WT1 GRIA3 MIPEP NDUFB3 PEX1 ARHGEF6 BRCA2 RNU4ATAC ERCC2 TGFB3 LAMA3 KCNAB2 FGF17 CTNS COL6A1 TRIO SPR ERCC5 NFKBIL1 PYGL ADAM17 DISP1 ANKLE2 UBE3B SLC26A3 ACSF3 CYP11B2 UBR1 EEF1A2 PET100 LMNA PROK2 KCNA1 NFE2L2 PEX3 HSPG2 LCK ACTB IARS1 ERCC6 MAGEL2 SLC25A13 NDUFAF4 GTF2IRD1 CAVIN1 SLC9A7 CHD7 FRMPD4 NHLRC2 NGLY1 STAG1 FANCM NOTCH2 PACS1 NELFA FDXR KCNJ11 GLI1 STXBP1 TGM1 ASS1 EXT1 TCF4 AIMP1 HLA-DPA1 KRT16 SETBP1 PIEZO2 GPC1 EBP SIM1 GNPTAB TJP2 NACC1 SDHA CDC6 HBA1 PHGDH RARA ACTL6B ATP6V0A2 STT3B CD81 POLG2 FIG4 NR0B1 MTHFR CD96 ERCC8 HLA-DPB1 DLD TERT PEX2 FOXH1 CLCN4 GABRA5 SURF1 BRF1 SLC22A4 MECP2 COL12A1 SERAC1 ALAD FGFR1 TRMT10A LMBRD1 SLC1A2 PQBP1 PTRH2 KMT2A GAS1 DLK1 GJA1 GMNN ACTB TRNW NEB CTLA4 EPAS1 MRAP COL6A2 ERCC3 CBS SNCA COG8 CDH23 LIG4 BLM PPP3CA CDON TINF2 ADA2 KCNJ1 RAG1 VPS51 ERCC2 DISP1 NDUFAF6 FLNA FAH CYP27B1 GALC MAP3K20 NF1 SIL1 DNMT3B RPL35 SDHAF2 CENPJ NAGS RTTN TCIRG1 CALR GNRHR TDGF1 TAPT1 TMEM216 FTSJ1 RFT1 COX15 SDHD SLC35A2 FGF8 CDC6 FLI1 DPYD HBA2 ERCC2 SDHC WDR4 CFTR TFRC GJB4 KIF1B ROBO1 GTPBP2 KMT2A MTRR CYB5R3 ORC4 DNM2 IPW ASCL1 ATXN7 GATA6 KCNJ18 AUH RMRP STAG2 UQCRFS1 KCNA2 MAX BMPR1A RYR1 IGHM HTT SLC25A15 NEUROG3 UNC80 MEFV SUCLA2 PALLD PTDSS1 NDUFAF8 MSX1 AHCY ATPAF2 FANCC POLR3A BCL6 SKIV2L PADI4 CA12 ALG3 CASK FANCI FAM111A NDUFS2 SDHC NDUFS1 HBB UBA5 MMAA CNTN1 PEX6 SELENON TRIM28 ZIC2 HTT SBDS RET CPLANE1 CYP11A1 KDM6A NDUFS2 DHDDS TUBB4A PEX14 CYP19A1 ZFP57 MAGEL2 ETHE1 FANCA NSDHL GABRA3 KLLN SCNN1B CSF2RA FBXW11 PTCH1 EPG5 GLI2 LBR PPP1CB ARID1B BCOR IL12A CEP152 MMUT CLDN16 POLG2 ALG11 XPC PMPCB MKRN3 CD96 MYH7 JAK3 DNAJC21 MPI BRAF RHBDF2 WRN TGFB1 LYRM7 NDUFB9 RPS26 SLC39A4 PROKR2 POLE CDH23 SFTPB FANCF THRB CACNA1A PEX10 SLC46A1 JAK1 RAI1 JMJD1C PALB2 GALT SHROOM4 NRXN1 IL12B COQ7 OCLN UFC1 TBX1 STAMBP COX4I2 RFXANK PEX12 KAT6B KRT1 B2M CORIN TIMM50 NR3C2 PLAA MADD KLHL41 LIMK1 PEPD MYT1L RPL5 HMGA2 GTPBP3 CNOT1 NDUFAF1 ERCC3 EP300 CDKN2A NDUFA6 MCCC1 DCLRE1C CDKL5 RPS10 POLG NDUFS2 MAP3K7 VAC14 ND3 RBBP8 BPTF SIN3A GNB1 BRCA2 NSUN2 BRAF EDNRB IGHM SLC39A8 PYCR1 PNPO DEAF1 NSDHL KRT5 PSMD12 CD3E INTU MLH1 CENPJ STAT3 BPTF TYMP ORC6 CUL7 RNF168 CD3G RARS2 LONP1 TMEM126B GRIN2D ARCN1 SUCLG1 ACAD9 HESX1 AMPD2 IGH POLG LPIN2 SLC12A3 GYS2 TGIF1 ADA SETBP1 DUSP6 MBL2 ZMIZ1 HLA-B SLX4 CYP17A1 MPDU1 CDT1 GOT2 RECQL4 ATP6V0A2 LEMD3 GABRD TSHR ITCH SEMA4A IRF2BP2 TRMT5 EHMT1 ASXL1 TRIM8 RPL5 RPS27 DOCK3 SURF1 RPS24 TRPV4 VPS33B RPL35A RET MC2R UFD1 ASAH1 HNRNPH2 UBE2T SRP54 GBA CHRNG CDT1 LAMB3 ERCC6 MMAB KANSL1 PTCH1 EIF2AK3 RECQL4 TDGF1 TALDO1 RAI1 HFE NDUFS2 LAT STXBP1 ZEB2 HLA-DQB1 SMC1A MAP2K1 ABCC8 PCCB NDUFAF4 ERCC4 OCRL SMC3 COG1 ARPC1B PDX1 PEX19 GATA1 DLL1 RBPJ MRPS7 SHH TPM3 H19-ICR SARS2 MTRR MYL2 HDAC8 MLH3 STAG2 TBL1XR1 ALG13 EFL1 AQP2 STT3A DNAJC3 KMT2C LIG4 ATP7B LRP12 SNAP29 SCN3A AHDC1 PQBP1 PLP1 ABCC8 FANCA DSP CYP7B1 ATR DLL1 COMT PRKCD BLNK AGTPBP1 WT1 LIPA RAG2 ADA ERCC4 RPS6KA3 SELENON AUTS2 CYTB SALL1 BTNL2 IGF1 GRIA3 CYP24A1 TGIF1 IGH ALG13 ACADS YY1AP1 NPM1 ATP6V0A2 ZBTB16 AGTR2 AHCY INSR COL7A1 MCM5 DDB2 CASK RTL1 SHH TUBB4A GABRG2 EGFR OSGEP LAMA3 IKZF1 ACSF3 YY1 HYMAI PIK3C2A AKT1 LMBRD1 AARS1 SCNN1B GALT GAA NEB PARN MRPS2 PNPT1 PTEN CASR RAB3GAP1 NDN RAD51C MPV17 GALE RAB39B PRDX1 REST TGFBR2 PRPS1 MTR IGH CLIP2 SCNN1B H19 TAZ IGF1R HIRA GNAS SVBP MEN1 COX1 HSD17B4 SIX3 FOXG1 PTF1A ELN MCCC2 GNRH1 CLCNKB PET100 ACTB FOXP3 ND4 IGHMBP2 PTS CBL SLC39A13 POLA1 TTR SON MAFB RPL11 GABRB2 PAM16 TET2 SPG11 HPDL PEX2 PCCA TTC37 DACT1 DAXX POLR1D NTRK2 KRT14 RPL15 SHH PKP1 TRNV TANC2 NUS1 SLC12A3 GHSR TRAC RNF13 OCRL IL21 SLC25A4 NDUFA11 NDUFS3 GBA TSPAN7 SLC35C1 HRAS C12ORF65 VPS13A EXT2 NOD2 NDUFA12 ADK GRIN2A TRNH RAG1 ORAI1 AGXT SNRPN TGFB1 PTPN11 PDE8B FGFR1 GATA2 IGF1 STAR MSMO1 TRMT1 ORC6 IFNGR1 SLC7A7 CACNA1S RARB GATA6 ND1 KMT2D WDR73 TKFC FOXRED1 LIPA MICOS13 ACAT1 TMEM216 STING1 PAK3 SUGCT FLNA DALRD3 HLA-DRB1 ZEB2 TNFRSF13C RPL18 AP1B1 CHRNA3 CCND1 KRT5 MRPS28 SLC2A3 PLP1 KIF15 ADA FIG4 MECP2 FLNA ND3 NUMA1 PDHA1 SCNN1G FBXL4 ASXL1 LARS1 F5 MED17 NSD2 HLA-DRB1 AP3B2 DDX6 KIF1B PTCH1 WNT2B ORC1 NDUFV1 FMR1 INS CYP11A1 ERCC4 CDON ST3GAL5 POLR3A GPT2 CCDC8 NDUFA13 BCORL1 SMOC1 NDUFA4 ATRX ACSL4 ND1 COG7 COG4 MID2 SLC34A1 HSD11B2 STAG2 ANOS1 NDUFAF3 PYCR2 HLA-DQA1 NACC1 RBM10 TP63 NUP214 FGF8 PDX1 GLYCTK CD244 PEX14 KANSL1 TNFSF12 NIPAL4 SLC11A1 NDUFS3 DGAT1 RPS28 NDN WDR11 SLC25A21 PANK2 MRPS16 C12ORF65 RAI1 NABP1 MC2R BSCL2 DPM2 NAGS BMP1 OCA2 MYMK PCGF2 FLCN DNAJC13 CAV1 BCAP31 DYRK1A RPS20 HLCS CYP17A1 NONO LAMC2 IL1RAPL1 NALCN ITCH ATM PTRH2 LYRM4 POLG NDUFS8 NDUFB8 IL6 RECQL4 NECTIN1 COL6A2 RAC2 JAK2 ATP8B1 TBL2 CFTR AKR1D1 EVC HERC1 DNM1L TAC3 METTL5 FANCE POC1A TGFB1 NEXMIF CSNK2A1 ATRIP MEG3 RFC2 GATA4 SNORD116-1 TMEM165 POLR2A NDUFAF5 RRM2B NEB TPM3 WDR4 FLT1 CD19 SURF1 EPCAM SIX3 SMARCD2 BRCA1 SELENON PSMB8 CDKN2B SZT2 HS6ST1 TRIP13 DNA2 MST1 CERS3 MRPL12 MMACHC CDON B4GALT7 SRSF2 NUP62 SMC1A FOXRED1 MEG3 AVPR2 MED12 CACNA1B COG6 CD79B LMNA PRDM16 STOX1 ASAH1 ACTL6A NDUFS7 MYPN ZIC2 ITGA7 NUBPL TRIT1 HADHA USP27X ACTA1 SPINK5 NDUFB3 EIF4G1 KCNJ6 SMAD4 DYNC2I1 ACTA1 HBB RERE MAD2L2 SKI HLA-DQB1 PLAG1 PIK3CA POR PGM3 ABCB11 EOGT WT1 PUS1 TRNW SMC1A SLC46A1 MTFMT ICOS PRNP RTTN RFX5 SDHC DCLRE1C SEC31A TLR4 COX7B PTCH1 IL2RG PRNP GLI2 PDHA1 OTULIN GAS1 TNFRSF13B TET2 NDUFA13 NDUFV1 RFXAP CARMIL2 CREB3L1 DPP6 MAGEL2 DGUOK STAT4 KISS1R PTEN H19 RUNX1 CYB5A RIPK1 NSMF MOGS UBA5 MYH3 UBAC2 MAP2K1 RIN2 BIRC3 SCN1B IKBKB PARS2 BMPR1A MMADHC NLRC4 KCNA4 NDN TMEM70 EXOSC8 DHCR24 SLC25A24 KRT17 ALPL AUH TRNL1 RET TRMT1 PEX5 SNRPN JAG1 ACVR1 FIP1L1 NDUFV2 ND5 NFIX CENPT WHCR DLG3 RFXANK ND6 HLA-B EP300 DDOST KCNJ18 MAGEL2 NDUFS4 AHDC1 HCFC1 HLA-DRB1 RPS29 NODAL GRM7 LRBA VDR ATP6 ERCC4 PYCR2 NDUFAF1 FUS RFT1 PROKR2 USP7 SLC25A11 RET FLII ATP6 DHCR24 RTEL1 HSD11B2 COA8 CLTCL1 KCNJ11 RLIM PIGQ ITGB4 INS HLA-B SDHA MVK
Protein Mutations 0
SNP 0

Reports

Data processed on December 13, 2020.

An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

Drug Reports   MeSH Reports   HPO Reports  

Interventions

4,818 reports on interventions/drugs

MeSH

706 reports on MeSH terms

HPO

306 reports on HPO terms

All Terms

Alphabetical index of all Terms

Google Colab

Python example via Google Colab Notebook